Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi€¦ · To the Board of Directors ofAcıbadem...

57
Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi Consolidated financial statements together with independent auditors’ report for the year ended December 31, 2018

Transcript of Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi€¦ · To the Board of Directors ofAcıbadem...

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi

Consolidated financial statements together with independent auditors’ report for the year ended December 31, 2018

.

Acıbadem Sağlık ve Hayat Sigorta

Anonim Şirketi and Its Subsidiary

TABLE OF CONTENTS: Independent Auditors’ Report on Consolidated Financial Statements

Consolidated Statement of Financial Position

Consolidated Statement of Profit or Loss and Other Comprehensive Income

Consolidated Statement of Changes in Equity

Consolidated Statement of Cash Flows

Notes to the Consolidated Financial Statements

Eyr Güney Bağımsız Denetim ve Tet: +90 212 375 3000SMMM A.Ş. Fax: +90 212 230 8291Meslek Mahallesi Eski Büyükdere ey.com

Building a better Cad. Orjin Meslek Plaza No: 27 Ticaret Sicil No 479920working world Sarıyer 34485

Istanbul - Türkiye

Acıbadem Sağlık ve Hayat Sigorta Anonim ŞirketiIndependent auditors’ report as of December 31, 2018

To the Board of Directors ofAcıbadem Sağlık ve Hayat Sigorta Anonim Şirketi;

Report on the audit of the financial statementsOpinion

We have audited the accompanying consolidated financial statements of Acıbadem Sağlık ve HayatSigorta Anonim Şirketi (“the Company”) and its subsidiary (“the Group”), which comprise theconsolidated statement offlnancial position as at December 31, 2018, and the consolidated statementof profit, consolidated statement of changes in equity and consolidated statement of cash flows for theyear then ended, and notes to the financial statements, including a summary of significant accountingpolicies.

in our opinion, the accompanying financial statements present fairly, in ali material respects, thefinancial position of the Group as at December 31 , 201 8 and of its financial performance and its cashflows for the year then ended in accordance with International Financial Reporting Standards.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Ourresponsibilities under those standards are further described in the Auditor’s responsibilities for theaudit of the financial statements section of our report. We are independent of the Group in accordancewith the International Ethics Standards Board for Accountants’ Code of Ethics for ProfessionalAccountants (IESBA Code) and we have fulfilled our other ethical responsibilities in accordance withthese requirements. We believe that the audit evidence we have obtained is sufficient and appropriateto provide a basis for our opinion.

Responsibilities of Management and Board of Directors for the financial statements

Management is responsible for the preparation and fair presentation of the financial statements inaccordance with IFRSs, and for such internal control as management determines is necessary toenable the preparation of financial statements that are free from material misstatement, whether dueto fraud or error.

in preparing the financial statements, management is responsible for assessing the Group’s ability tocontinue as a going concern, disclosing, as applicable, matters related to going concern and using thegoing concern basis of accounting unless management either intends to liquidate the Group or tocease operations, or has no realistic alternative but to do so.

Board of Directors are responsible for overseeing the Group’s financial reporting process.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a wholeare free from material misstatement, whether due to fraud or error, and to issue an auditor’s report thatincludes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee thatan audit conducted in accordance with ISAs wilI always detect a material misstatement when it exists.Misstatements can arise from fraud or error and are considered material if, individually or in theaggregate, they could reasonabiy be expected to influence the economic decisions of users taken onthe basis of these financial statements.

A member 5m of Ernst Young Global Lımıfed

EYBuilding a betterworking world

As part of an audit in accordance with ISAs, we exercise professional judgment and maintainprofessional scepticism throughout the audit. We also:

. Identify and assess the risks of material misstatement of the financial statements, whether dueto fraud or error, design and perform audit procedures responsive to those risks, and obtainaudit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk ofnot detecting a material misstatement resulting from fraud is higher than for one resulting fromerror, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or theoverride of internal control.

. Obtain an understanding of internal control relevant to the audit in order to design auditprocedures that are appropriate in the circumstances, but not for the purpose of expressing anopinion on the effectiveness of the Group’s internal control.

. Evaluate the appropriateness of accounting policies used and the reasonableness of accountingestimates and related disclosures made by management.

. Conclude on the appropriateness of management’s use of the going concern basis ofaccounting and, based on the audit evidence obtained, whether a material uncertainty existsrelated to events or conditions that may cast significant doubt on the Group’s ability to continueas a going concern. If we conclude that a material uncertainty exists, we are required to drawattention in our auditor’s report to the related disclosures in the financial statements or, if suchdisclosures are inadequate, to modify our opinion. Our conclusions are based on the auditevidence obtained up to the date of our auditor’s report. However, future events or conditionsmay cause the Group to cease to continue as a going concern.

. Evaluate the overail presentation, structure and content of the financial statements, includingthe disclosures, and whether the financial statements represent the underiying transactions andevents in a manner that achieves fair presentation.

. Obtain sufficient appropriate audit evidence regarding the financial information of the entities orbusiness activities within the Group to express an opinion on the consolidated financialstatements. We are responsible for the direction, supervision and performance of the groupaudit. We remain soleiy responsible for our audit opinion.

We communicate with Board of Directors regarding, among other matters, the planned scope andtiming of the audit and significant audit findings, including any significant deficiencies in internal controlthat we identify during our audit.

The name of the engagement partner who supervised and concluded this audit is Fatih Polat.

Güney enetim ve Serbest Muhasebeci Mali Müşavirlik Anonim Şirketi

!:\ oungGlobalLimited

F iho

7 , /

E agnıentPer 1

February 28, 2019Istanbul, Turkey

2

A member firm ofErnst Young Global Limited

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Consolidated Statement of Financial Position

At 31 December 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

3

Audited Audited

Notes

December 31,

2018

December 31,

2017

ASSETS

Cash and cash equivalents 7 125,552,189 109,990,448

Financial assets at fair value through profit or loss 8 12,900,044 1,395,474

Premium and other insurance receivables 10 141,953,199 104,713,879

Due from insurance and reinsurance companies 11 72,980,013 47,843,856

Investment securities 8 624,240,202 540,780,284

Reinsurance assets 22 11,655,073 9,927,037

Deferred acquisition costs 18 38,865,755 31,108,984

Property and equipment, net 15 4,063,260 3,895,817

Intangible assets, net 16 3,333,636 3,681,285

Deferred tax assets 17 9,907,453 6,211,484

Other assets 13 41,115,730 16,464,024

Total assets 1,086,566,554 876,012,572

LIABILITIES AND EQUITY

Financial liabilities 9 170,807 304,066

Due to reinsurance companies 11 3,589,385 4,352,512

Other insurance payables 12 7,972,683 7,548,213

Payables to medical networks 12 136,993,707 128,006,424

Insurance contract liabilities 22 467,807,414 340,764,224

Investment contract liabilities 23 11,460,198 13,549,664

Income taxes payable 17 - 2,868,342

Employee benefits 19 26,769,441 15,661,185

Other provisions 20 18,724,155 16,738,766

Other liabilities 21 18,123,768 48,227,980

Total liabilities 691,611,558 578,021,376

Share capital 24 119,010,960 119,010,960

Fair value reserve of available-for-sale

financial assets (1,514,766) 4,943,848

Legal reserves 24 9,126,051 5,945,070

Retained earnings 268,332,751 168,091,318

Equity attributable to owners of the Group 394,954,996 297,991,196

Total liabilities and equity 1,086,566,554 876,012,572

The notes on pages 7 to 54 are an integral part of these consolidated financial statements.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

4

Audited Audited

Notes 2018 2017 Gross premiums earned 22 1,053,031,574 856,269,860

Premiums ceded to reinsurers 22 (20,036,943) (16,807,612)

Net premiums 22 1,032,994,631 839,462,248

Fees and commission income 25 416,832 371,084

Investment income 27 134,400,219 79,272,795

Other technical income 29 5,851,684 5,615,995

Other income 28 510,735 374,018

Total income 1,174,174,101 925,096,140

Gross benefits and claims paid 22 (860,102,333) (698,300,050)

Claims ceded to reinsurers 22 21,071,306 16,684,378

Gross changes in insurance contract liabilities 22 (38,649,104) (19,956,188)

Changes in insurance contract liabilities ceded to reinsurers 22 675,729 2,384,355

Gross change in investment contract liabilities (1,287,589) (2,627,200)

Net benefits and claims (878,291,991) (701,814,705)

Commission expenses 18 (73,435,259) (66,503,859)

Other operating and administrative expenses 26 (90,287,754) (71,802,853)

Finance costs 27 (1,517,799) (239,949)

Other technical expenses 29 - (4,283,966)

Other expenses 28 1,064,666 (790,555)

Total expenses (1,042,468,137) (845,435,887)

Profit before taxes 131,705,964 79,660,253

Income tax expenses 17 (28,283,550) (15,908,643)

Profit for the year 103,422,414 63,751,610

Other comprehensive income:

Items that are or may be reclassified subsequently to profit or loss:

Net changes in fair values of available-for sale-financial

assets owned by the Group (9,290,340) 6,672,615

Net changes in fair values of available-for-sale financial

assets backing investment contract liabilities (123,839) (18,638)

Foreign exchange effect of available-for-sale financial

assets backing investment contract liabilities 2,157,068 (30,503)

Net changes in fair values of available-for-sale financial

assets owned by the Group, transferred to profit or loss (868,452) (42,750)

Net changes in fair values of available-for-sale financial

assets backing investments contract liabilities,

transferred to profit or loss (28,062) (5,059)

Related tax 1,695,011 (1,315,133)

Items that will never be reclassified to profit or loss

Actuarial gains/(losses) on employee severance indemnity 19 - (8,378)

Related tax - 1,675

Other comprehensive income for the year, net of tax (6,458,614) 5,253,829

Total comprehensive income for the year 96,963,800 69,005,439

The notes on pages 7 to 54 are an integral part of these consolidated financial statements.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Consolidated Statement of Changes in Equity

For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

5

Share

capital

Fair value reserve of

available-for-sale

financial assets

Legal

reserves Retained earnings Total

Balances at December 31, 2016 119,010,960 (316,684) 4,341,372 105,950,109 228,985,757

Total comprehensive income for the year

Profit of the year - - - 63,751,610 63,751,610

Other comprehensive income, net of tax - 5,260,532 - (6,703) 5,253,829

Total comprehensive income for the year - 5,260,532 - 63,744,907 69,005,439

Transactions with equity holders, recognised directly in equity

Transfers - - 1,603,698 (1,603,698) -

Total contributions from and distributions to equity holders - - 1,603,698 (1,603,698) -

Balances at December 31, 2017 119,010,960 4,943,848 5,945,070 168,091,318 297,991,196

Balances at December 31, 2017 119,010,960 4,943,848 5,945,070 168,091,318 297,991,196

Total comprehensive income for the year

Profit of the year - - - 103,422,414 103,422,414

Other comprehensive income, net of tax - (6,458,614) - - (6,458,614)

Total comprehensive income for the year 119,010,960 (6,458,614) - 103,422,414 96,963,800

Transactions with equity holders, recognised directly in equity

Transfers - - 3,180,981 (3,180,981) -

Total contributions from and distributions to equity holders - - 3,180,981 (3,180,981) -

Balances at December 31, 2018 119,010,960 (1,514,766) 9,126,051 268,332,751 394,954,996

The notes on pages 7 to 54 are an integral part of these consolidated financial statements.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Consolidated Statement of Cash Flows

For the Year Ended 31 December 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

6

Audited Audited

Notes 2018 2017

Cash flows from operating activities: Profit for the year 103,422,414 63,751,610

Adjustments for: Current and deferred tax charge 17 28,283,550 15,908,643

Depreciation and amortisation 26 2,415,269 1,934,406

Provision for employee severance indemnity 19 2,182,340 1,667,005 Provision for vacation pay liability 19 860,519 213,734

Provision for short term and long term employee benefits 20,357,168 12,044,484

Change in other provisions 20 1,985,389 1,724,749 Claims reported during the year and change in claims estimation incurred in

previous years, gross 22

898,751,439

718,256,238

Change in reserve for unearned premiums, gross 22 90,190,039 56,321,708 Change in life mathematical reserves for long term contracts 22 (1,796,055) 1,695,607

Provision for doubtful receivables, net 28 (746,938) 568,012

Gains from disposal of property and equipment 94,791 19,311 Net interest and trading income (127,067,502) (82,486,900)

Unrealized foreign exchange gains and losses on investment securities (77,412,621) (21,014,412)

Changes in operating activities:

Change in premium and other insurance receivables (40,605,712) (17,748,702)

Change in receivables from insurance and reinsurance companies (25,483,831) (14,730,342) Change in reinsurance assets 22 (1,728,036) (3,403,393)

Change in other assets (24,651,706) (1,854,457)

Change in deferred acquisition costs 18 (7,756,771) (3,397,660)

Change in investment contract liabilities (2,086,466) (3,237,154)

Change in due to reinsurance companies (763,127) 2,006,512

Change in other insurance payables 536,758 (33,130) Change in payables to medical networks 10,765,044 37,769,148

Change in other liabilities (30,237,471) 7,200,389

Change in loan and receivables backing investment contracts 3,516,805 (3,682,732) Change in blocked cash at banks 12,368,855 (9,336,902)

Change in loan and receivables with original maturity more than 3 months 57,486,019 (27,333,938)

Claims paid, gross 22 (860,102,333) (698,300,050) Employee severance indemnity paid 19 (609,371) (498,862)

Unused vacations paid 19 - (97,670)

Personnel bonuses paid (11,682,400) (3,812,484) Income taxes paid (24,524,780) (15,085,817)

Net cash from operating activities (4,041,661) 15,026,951

Cash flows from investing activities: Acquisition of property and equipment 15 (1,768,033) (576,114)

Acquisition of intangible assets 16 (555,260) (2,097,457)

Proceeds from financial assets at fair value through profit or loss 8 (12,900,044) 109,150

Acquisition of available-for-sale financial assets 8 (259,158,663) (263,106,119) Proceeds from sale of available-for-sale financial assets 8 93,112,983 175,203,773

Acquisition of HTM financial assets (6,036,398) -

Interest received 211,635,723 105,660,662 Interest paid 335,966 (14,903)

Net cash from investing activities 24,666,274 15,178,992

Cash flows from financing activities: Proceeds from obligations under repurchase agreements - -

Payment of obligations under repurchase agreements - -

Net cash from financing activities - -

Net increase in cash and cash equivalents 20,624,613 30,205,943

Cash and cash equivalents at January 1 7 104,780,348 74,574,405

Cash and cash equivalents at December 31 7 125,404,961 104,780,348

The notes on pages 7 to 54 are an integral part of these consolidated financial statements.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

Note description Page

1 Reporting entity 7

2 Basis of preparation 7-8

3 Significant accounting policies 9-25

4 Critical accounting estimates and judgments in applying accounting policies 25

5 Management of insurance risk 26-28

6 Management of financial risk 29-36

7 Cash and cash equivalents 36

8 Investment securities 37-40

9 Financial liabilities 41

10 Premium and other insurance receivables 42

11 Amounts due from/to reinsurance companies 42

12 Payables to medical networks and other insurance payables 42

13 Other assets 43

14 Investment properties, net 43

15 Property and equipment, net 43

16 Intangible assets, net 44

17 Income taxes 44-45

18 Deferred acquisition costs 45-46

19 Employee benefits 46

20 Other provisions 46

21 Other liabilities 47

22 Insurance contract liabilities 47-49

23 Investment contract liabilities 50

24 Equity 50-51

25 Fees and commission income 51

26 Operating expenses 51

27 Investment income and finance costs 52

28 Other income and expenses 52

29 Other technical income and expenses 52

30 Blocked securities and bank deposits 53

31 Related party balances and transactions 53

32 Contingencies 53

33 Subsidiaries 54

34 Other 54

35 Subsequent event 54

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended 31 December 2018 (Currency: Turkish Lira (TL) unless otherwise indicated)

7

1 Reporting entity

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi (“the Company”) was established to operate in whole

kinds of underwriting activities within the scope of life insurance and especially life, personal accident,

health and sickness insurances as well as co-insurance, re-insurance and retrocession operations within

the boundaries of Turkey and in foreign countries. The Company initiated insurance activities in 1994,

executing insurance policies and investment contracts in life, personal accident and health branches.

On 6 February 2004, shares representing 99.72% of the Company’s capital was purchased by Mehmet

Ali Aydinlar from Savings Deposit Insurance Fund. Following the formal approval given by the

Republic of Turkey Prime Ministry Under Secretariat of Treasury (the “Turkish Treasury”) on 13

November 2007, 50.0% of the Company shares were transferred to Walnut Holding Cooperaite U.A.

operating under Abraaj Capital which is an international investment company, through share increase

method in accordance with the resolution of the Board of Directors held on December 17, 2007.

Following the approval of Turkish Treasury on November 1, 2013, shares representing 40.0% of the

Company’s capital owned by Mehmet Ali Aydınlar and shares representing 50.0% of the Company’s

capital owned by Walnut Holding Cooperaite U.A. has been transferred to Burau Ventures Sdn Bhd, a

fully owned subsidiary of Avicennia Capital Sdn Bhd that is in turn a fully owned subsidiary of

Khazanah Nasional Berhad. In 2016, Burau Ventures Sdn Bhd acquired remaining shares hold by

Mehmet Ali Aydınlar representing 10% of the Company’s paid in capital.

Khazanah Nasional Berhad that manages the strategic investment funds of the Malaysian Government

owns investments in over 50 companies, amounting to more than 110.8 billion Malaysian Ringgit and

outside Malaysia, operates mainly in India, China, Singapore and Turkey. Khazanah Nasional Berhad

also owns approximately 75% of shares of Acıbadem Sağlık Yatırımları Holding AŞ in Turkey.

The consolidated financial statements of the Company as at and for the year ended December 31, 2018

comprises the Company and its subsidiary (together referred to as the “Group” and individually as

“Group Entities”).

The Group has 559 employees as at December 31, 2018 (December 31, 2017: 522 employees).

The address of the registered office of the Company is as follows:

Küçükbakkalköy Mah. Başar Sok. No: 20

34750 Ataşehir Istanbul – Turkey

The Company’s consolidated financial statements as of December 31, 2018 are approved and

authorized for issuance as of February 18, 2019 by Company Management”.

2 Basis of preparation

a) Statement of compliance

The accompanying consolidated financial statements of the Group have been prepared in accordance

with International Financial Reporting Standards (IFRSs). The Group adopted all IFRSs, which were

mandatory as at December 31, 2018.

b) Basis of measurement

The accompanying consolidated financial statements are prepared in accordance with historical cost

basis as adjusted for the effects of inflation that lasted until December 31, 2005, except for items

measured at fair value that are financial assets at fair value through profit or loss, derivative financial

assets and liabilities, available-for-sale financial assets and investment contract liabilities which are

measured at their fair values.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended 31 December 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

8

2 Basis of preparation (continued)

c) Functional and presentation currency

The accompanying consolidated financial statements are presented in TL, which is the Group Entities’

functional currency.

d) Accounting in hyperinflationary countries

The consolidated financial statements of the Group has been restated for the changes in the general

purchasing power of the Turkish Lira based on International Accounting Standards (“IAS”) IAS 29 –

Financial Reporting in Hyperinflationary Economies until December 31, 2005. IAS 29 requires that

financial statements prepared in the currency of a hyperinflationary economy be stated in terms of the

measuring unit current at the reporting date, and that corresponding figures for previous periods be restated

in the same terms. One characteristic that necessitates the application of IAS 29 is a cumulative three-year

inflation rate approaching or exceeding 100%. The cumulative three-year inflation rate in Turkey was

35.61% as at December 31, 2005, based on the Turkish nation-wide wholesale price indices announced by

the Turkish Statistical Institute. This, together with the sustained positive trend in qualitative factors, such

as the stabilisation in financial and monetary markets, decrease in interest rates and the appreciation of TL

against the US Dollar and other hard currencies have been taken into consideration to categorise Turkey

as a non-hyperinflationary economy under IAS 29 effective from January 1, 2006.

e) Significant accounting estimates and judgements

The preparation of the consolidated financial statements in conformity with IFRSs requires management

to make judgments, estimates and assumptions that affect the application of accounting policies and the

reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting

estimates are recognised in the period in which the estimate is revised and in any future periods affected.

In particular, information about significant areas at estimation uncertainty and critical judgment in

applying accounting policies that have the most significant effect on the amounts recognised in the

consolidated financial statements are described in the following notes:

Note 4 – Critical accounting estimates and judgments in applying accounting policies

Note 5 – Management of insurance risk

Note 6 – Management of financial risk

Note 10 – Premium and other insurance receivables

Note 17 – Income taxes

Note 18 – Deferred acquisition costs

Note 19 – Employee benefits

Note 20 – Other provisions

Note 22 – Insurance contract liabilities

Note 23 – Investment contract liabilities

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

9

3 Significant accounting policies

The accompanying consolidated financial statements include the accounts of the Group Entities on the

basis set out in sections below.

a) Basis of consolidation

The accompanying consolidated financial statements comprise the financial statements of the parent

company (“Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi”) and its subsidiary (“Acıbadem Grubu

Sigorta Aracılık Hizmetleri Anonim Şirketi”, wholly owned by the Company) prepared on the basis set

out in sections below. The consolidated financial statements of the entities included in the consolidation

have been prepared as at the date of these consolidated financial statements.

Subsidiary

Subsidiary is the entity controlled by the Group. The financial statements of the subsidiary is included in

the consolidated financial statements from the date that control commences.

Transactions eliminated on consolidation

Intra-group balances and transactions, and any unrealised income and expenses arising from intra-group

transactions, are eliminated in preparing the consolidated financial statements.

b) Foreign currency

Foreign currency transactions

Monetary assets and liabilities denominated in foreign currencies are translated into the functional

currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured

at fair value in a foreign currency are translated into the functional currency at the exchange rate when

the fair value was determined. Non-monetary items that are measured based on historical cost in a foreign

currency are translated at the exchange rate at the date of the transaction. Foreign currency differences

are generally recognized in profit or loss.

However, foreign currency differences arising from the translation of the following items are recognized

in OCI:

available-for-sale equity investments (except on impairment, in which case foreign currency

differences that have been recognised in OCI are reclassified to profit or loss);

Foreign currency exchange rates used by the Group as at respective dates are as follows:

Dates US Dollar / TL Euro / TL

December 31, 2018 5.2609 6.0208

December 31, 2017 3.7719 4.5155

As written on the face of the saving life policies executed by the Group, investment contract liabilities are

translated into TL by using effective foreign exchange selling rates announced by the Central Bank of

Turkey which were 5.2783 US Dollar/TL and 6.0479 Euro/TL as at reporting date (December 31, 2017:

3.7843 US Dollar/TL and 4.5305 Euro/TL).

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

10

3 Significant accounting policies (continued)

c) Insurance premiums

Premiums are recognised on the date on which the policy commences. Premiums also include any

adjustments arising in the accounting period for premiums receivable in respect of business written in

prior accounting periods. Rebates that form part of the premium rate, such as no-claim rebates, are

deducted from the gross premiums when due. Premiums are shown before deduction of commissions

given or received and deferred acquisitions costs, and are gross of any taxes and duties levied on

premiums.

Reinsurance premiums written comprise the total premiums payable for the whole cover provided by

contracts entered into the period and are recognised on the date on which the policy incepts. Premiums

include any adjustments arising in the accounting period in respect of reinsurance contracts incepting in

prior accounting periods.

For short-term insurance contracts (refer to accounting policy (n)), premiums are recognised as revenue

(net insurance premium revenue) in profit or loss, net of premiums ceded to reinsurance firms,

proportionally over the period of coverage. The portion of premiums received on in-force contracts that

relates to unexpired risks at reporting date is recognised as the reserve for unearned premiums (refer to

accounting policy (p)).

For long-term insurance contracts (refer to accounting policy (n)), premiums are recognised as revenue in

profit or loss when the premiums are due from the policyholders.

Amounts collected as premiums from investment contracts (refer to accounting policy (n)), are not

recognised as revenue in profit or loss. Premiums for such contracts are reported as deposits in the

consolidated statement of financial position as investment contract liabilities.

d) Fees and commission income and commission expenses

Commission income and expenses comprise commissions received from reinsurance companies and

commissions paid to the intermediaries, respectively. Commission income and commission expenses are

recognised based on accrual basis over the life of the related insurance policies.

Commissions earned from the intermediary operations of the Group on behalf of other insurance

companies for property and casualty insurance products (refer to accounting policy (n)) are recognised as

revenue at the inception of the contracts.

Other fees and commission income, especially for the fees charged to other parties for the services

provided as third party administrator by the Group is recognised as the related services are performed.

e) Interest

Interest income and expenses are recognised in profit or loss using the effective interest method. The

effective interest rate is the rate that exactly discounts the estimated future cash receipts and payments

through the expected life of the financial assets or liabilities (or, where appropriate, a shorter period) to

the carrying amount of the financial assets or liabilities. When calculating the effective interest rate, the

Group estimates future cash flows considering all contractual terms of the financial instrument but not

future credit losses.

The calculation of the effective interest rate includes all fees and points paid or received transaction costs,

and discounts or premiums that are an integral part of the effective interest rate. Transaction costs are

incremental costs that are directly attributable to the acquisition, issue or disposal of financial assets or

liabilities. Interest income and expenses presented in the consolidated statement of comprehensive income

includes:

interest on financial assets and liabilities at amortised cost on an effective interest rate basis,

interest on available-for-sale financial assets on an effective interest rate basis,

interest earned till the disposal of financial assets at fair value through profit or loss.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

11

3 Significant accounting policies (continued)

f) Trading income, net

Net trading income includes gains and losses arising from disposal of financial assets at fair value through

profit or loss and available-for-sale financial assets and gains and losses on derivative financial

instruments held for trading purpose.

g) Claims, net of ceded

Benefits and claims include all claims occurring during the period, whether reported or not, related

internal and external claims handling costs that are directly related to the processing and settlement of

claims, a reduction for the recoveries, and any adjustments to claims outstanding from previous years.

Claims are recognised in the period in which they occur, based on reported claims or on the basis of

estimates when not reported. Full provision is accounted for the claims outstanding, including claim

settlements reported at the reporting date. Incurred but not reported claims are also provided for under the

claims provision.

Reinsurance claims are recognised when the related gross insurance claim is recognised according to the

terms of the relevant contract.

h) Property and equipment

The cost of the property and equipment acquired before January 1, 2006 are restated for the effects of

inflation in TL unit current at December 31, 2005 pursuant to IAS 29. The property and equipment

acquired subsequent to this date are recorded at their historical costs. Accordingly, property and

equipment are carried at costs less accumulated depreciation and impairment losses, if any.

Depreciation is calculated using the straight-line method to write down the cost of such assets to their

residual values over their estimated useful lives as follows:

Property and equipment Estimated useful lives (years)

Buildings 50

Furniture and fixtures 3-15

Other tangible assets (including leasehold improvements) 5

Assets obtained through finance leases 5

Gains/losses arising from the disposal of the property and equipment are recognised in profit or loss and

calculated as the difference between the net book value and the net sales price.

There are no changes in the accounting estimates that are expected to have an impact in the current or

subsequent periods.

Expenditures incurred to replace a component of a tangible asset that is accounted for separately, and

major inspection and overhaul costs, are capitalised. Other subsequent expenditures are capitalised only

when it increases the future economic benefits embodied in the item of tangible assets. All other

expenditures are reflected as expense in profit or loss as incurred.

i) Intangible assets

The Group’s intangible assets consist of rights and software programs. Intangible assets are recorded at

cost. The costs of the intangible assets purchased before January 1, 2006 are restated from the purchasing

dates to December 31, 2005, the date the hyperinflationary period is considered to be ended. The

intangible assets purchased after this date are recorded at their historical costs. The intangible assets are

amortised based on straight line amortisation. The economic lives of intangible assets vary within the

range of three and fifteen years and hereby the amortisation rates applied are within 33.33% and 6.66%.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

12

3 Significant accounting policies (continued)

j) Impairment of non-financial assets

The carrying amounts of the Group’s non-financial assets, other than deferred tax assets, are reviewed at

each reporting date to determine whether there is any indication of impairment. If any such indication exists

for as particular asset or a group of assets, then that asset’s recoverable amount is estimated.

An impairment loss is recognised if the carrying amount of an asset or its cash-generating unit exceeds its

recoverable amount. A cash-generating unit is the smallest identifiable asset group that generates cash flows

that largely are independent from other assets and groups. Impairment losses are recognised in profit or loss.

The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value

less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present

value using a pre-tax discount rate that reflects current market assessments of the time value of money and

the risks specific to the asset.

Impairment losses in respect of other assets, impairment losses recognised in prior periods are assessed at

each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is

reversed if there has been a change in the estimates used to determine the recoverable amount. An

impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying

amount that would have been determined, net of depreciation or amortisation, if no impairment loss had

been recognised.

k) Leases

Finance leases

Leases of property and equipment where the Company has substantially all the risks and the rewards of

ownership are classified as finance leases. Finance leases are capitalised at the inception of the lease at

the lower of the fair value of the leased property or the present value of the minimum lease payments.

Each lease payment is allocated between the liability and finance charges so as to achieve a constant rate

on the principal balance outstanding. The corresponding rental obligations, net of finance charges, are

included in other payables and provisions. The interest element of the finance cost is charged to the

consolidated statement of comprehensive income over the lease period. The property and equipment

acquired under finance leases is depreciated over the shorter of the useful life of the asset or the lease

term.

If there is impairment in the value of the assets obtained through finance lease and in the expected future

benefits, the leased assets are written down to their recoverable amount. Depreciation for assets obtained

through finance lease is calculated in the same manner as other tangible assets.

Operational leases

Payments made under operating leases are recognised in profit or loss on a straight-line basis over the

term of the lease.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

13

3 Significant accounting policies (continued)

l) Financial instruments

Recognition

The Group initially recognises loans and advances on the date which they are originated. All other

financial assets and liabilities are initially recognised on the date of settlement at which the related

financial instruments are transferred from the counterparties physically.

A financial asset or liability is measured initially at fair value plus, for an item not at fair value through

profit or loss, transaction costs that are directly attributable to its acquisition or issue.

Classification

The Group classifies its investments into the following categories: financial assets at fair value through

profit or loss, loans and receivables, held-to-maturity investments securities and available-for-sale

financial assets. The classification depends on the purpose for which the investments were acquired.

Management determines the classification of its financial assets at initial recognition and re-evaluates this

at every reporting date.

Financial assets at fair value through profit or loss (“FAAFTPL”) are the financial assets, classified into

this category at inception if acquired principally for the purpose of selling in the short term, if it forms

part of a portfolio of financial assets in which there is evidence of short term profit making.

Held-to-maturity investment securities are financial assets with fixed or determinable payments and fixed

maturity that the Group has the positive intent and ability to hold to maturity. These include certain debt

securities.

Available-for-sale financial assets intended to be held for an indefinite period of time, which may be sold

in response to needs for liquidity or changes in interest rates, exchange rates or equity prices, are classified

as available-for-sale.

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are

not quoted in an active market other than those that the Group intends to sell in the short term or that it

has as at fair value through profit or loss or available-for-sale. They arise when the Company provides

money, goods and services directly to a debtor with no intention of trading the receivable.

Financial liability is any liability that is a contractual obligation to deliver cash or another financial asset

to another entity.

See also specific instruments below.

Measurement

Subsequent to initial recognition, all financial assets at fair value through profit or loss and all available-

for-sale financial assets are measured at fair value, except that any instrument that does not have a quoted

market price in an active market and whose fair value cannot be reliably measured is stated at cost,

including transaction costs, less impairment losses.

All non-trading financial liabilities, loans and receivables and held-to-maturity investments are measured

at amortised cost less impairment losses. The amortised cost of a financial asset or liability is the amount

at which the financial asset or liability is measured at initial recognition, minus principal repayments, plus

or minus the cumulative amortisation using the effective interest method of any difference between the

initial and the maturity amounts, minus any reduction for impairment.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

14

3 Significant accounting policies (continued)

l) Financial instruments (continued)

Fair value measurement principles

The fair value of financial instruments is based on their quoted market price at the reporting date without

any deduction for transaction costs. If a quoted market price is not available, the fair value of the

instrument is estimated using pricing models or discounted cash flow techniques. Where discounted cash

flow techniques are used, estimated future cash flows are based on management’s best estimates and the

discount rate is a market related rate at the reporting date for an instrument with similar terms and

conditions. Where pricing models are used, inputs are based on market related measures at the reporting

date.

Gains and losses on subsequent measurement

Gains and losses arising from changes in the fair value of financial assets at fair values through profit or

loss are recognised in the investment income in the period in which they arise. Unrealised gains and losses

arising from changes in the fair values of available-for-sale financial assets are recognised in other

comprehensive income except to the extent that they qualify for assets backing liabilities (investment

contracts). When available-for-sale financial assets are sold or impaired, the accumulated fair value

adjustments recognised in other comprehensive income are transferred to the profit or loss as net realised

gains/losses on financial assets.

Derecognition

A financial asset is derecognised when the control over the contractual rights that comprise that asset, is

lost. This occurs when the rights are realised, expire or are surrendered. A financial liability is

derecognised when it is extinguished.

Available-for-sale financial assets and financial assets at fair value through profit or loss that are sold are

derecognised and corresponding receivables from the buyer for the payment are recognised as at the date

the Group commits to sell the assets. The specific identification method is used to determine the gain or

loss on derecognition.

Loans and receivables are derecognised on the day they are transferred by the Group.

Offsetting

Financial assets and liabilities are offset and the net amount is reported in the consolidated statement of

financial position when there is a legally enforceable right to set off the recognised amounts and there is

an intention to settle on a net basis or realise the asset and settle the liability simultaneously.

Specific instruments

Cash and cash equivalents: For the purposes of the consolidated statement of cash flows, cash and cash

equivalents comprise cash on hand and short-term cash at banks with an original maturity of three months

or less except for cash at banks collateralised in favour of the Turkish Treasury.

Loans to the policyholders are the securitised loans that are used by the policyholders with the security of

their life policies that have made premium payments throughout a certain period, determined by the

technical bases related to certified tariffs of life policies (this period is 3 years according to general

conditions of life insurance). As at December 31, 2018, total amount of loans to the policyholders amounts

to TL 678,259 (December 31, 2017: TL 533,382) (Note 10).

Investment in equity participations are measured at cost as adjusted to reflect the effect of inflation as of

December 31, 2005 less impairment losses, if any.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

15

3 Significant accounting policies (continued)

l) Financial instruments (continued)

Specific instruments (continued)

Investment securities: Investment securities are the financial assets that are classified as held-to-maturity

financial assets and available-for-sale financial assets.

Assets backing liabilities are the financial assets invested against the savings of the life policyholders

which are classified as investment contract liabilities in the accompanying consolidated statement of

financial position. In accordance with the prevailing legislation assets backing liabilities could be

classified as financial assets at fair value through profit or loss, loans and receivables, held-to-maturity

investment securities and available-for-sale financial assets by considering the benefits of the

policyholders and measured in accordance with the principles as stated above.

See also accounting policy regarding investment contracts (n).

Time deposits at banks are the assets deposited at banks with an original maturity of more than three

months on behalf of the Group or the policyholders for earning interest.

Repurchase transactions: The Group enters into purchases/sales of investments under agreements to

resell/repurchase the same investments at a certain date in the future at a fixed price. Investments

purchased subject to commitments to resell them at future dates are not recognised in the accompanying

consolidated financial statements. The amounts paid are recognised as receivables from reverse

repurchase agreements in the accompanying consolidated financial statements. The receivables are shown

as collateralised by the underlying security. Investments sold under repurchase agreements continue to be

recognised in the consolidated statement of financial position and are measured in accordance with the

accounting policy applicable for the financial instrument group they are classified in.

Finance income and expenses arising from the repurchase and resale agreements over investments are

recognised on an accruals basis over the period of the transaction and are included in “interest income”

or “interest expense” in the accompanying consolidated profit or loss.

m) Impairment of financial assets

At each reporting date the Group assesses whether there is objective evidence that financial assets are

individually impaired. In determining whether an impairment loss should be recorded in profit or loss, the

Group makes judgments as to whether there is any observable data indicating that there is a measurable

decrease in the estimated amounts recoverable from individual financial asset. Objective evidence that a

financial asset is impaired includes observable data that comes to the attention of the Group about the

following loss events:

(a) significant financial difficulty of the counterparty (agency or debtor);

(b) a breach of contract, such as a default or delinquency in interest or principal payments by more

than 60 days;

(c) it is probable that the counterparty will declare bankruptcy or enter into other financial

reorganisation;

(d) the disappearance of an active market for the related financial asset because of financial

difficulties; or

(e) observable data indicating that there is a measurable decrease in the estimated future cash flows

from a group of financial assets since the initial recognition of those assets, although the decrease

cannot yet be identified with the individual financial assets in the group, including:

(i) adverse changes in the payment status of counterparties; or

(ii) national or local economic conditions that correlate with defaults on the assets in the group.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

16

3 Significant accounting policies (continued)

m) Impairment of financial assets (continued)

If there is objective evidence that there occurs an impairment loss on receivables, the amount of the loss

is measured based on the difference between the asset’s carrying amount and the estimated recoverable

amount. The carrying amount of the asset is reduced through the use of an allowance account. The amount

of the loss is recognised in profit or loss.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related

objectively to an event occurring after the impairment was recognised (such as an improvement in the

debtor’s credit rating), the previously recognised impairment loss is reversed by adjusting the allowance

account. Any subsequent reversal of impairment loss is recognised in profit or loss, to the extent that the

carrying value of the asset does not exceed its cost at the reversal date.

If an available-for-sale investment security is impaired, an amount comprising the difference between its

cost (net of any principal payment and amortisation) and its current fair value, less any impairment loss

previously recognised in profit or loss, is transferred from other comprehensive income to profit or loss

as a reclassification adjustment. If, in a subsequent period, the fair value of an impaired available-for-sale

debt security increases and the increase can be objectively related to an event occurring after the

impairment loss is reversed, with the amount of the reversal recognised in profit or loss. However, any

subsequent recovery in the fair value of an impaired available-for-sale equity security is recognised in

other comprehensive income.

A write off is made when all or part of a receivable is deemed uncollectible or in the case of debt

forgiveness. Such receivables are written off after all the necessary procedures have been completed and

the amount of the loss has been determined. Write offs are charged against previously established

allowances and reduce the amount of the receivables. Subsequent recoveries of amounts previously

written off are included in profit or loss.

The methodology and assumptions used for estimating both the amount and timing of recoverable

amounts are reviewed regularly to reduce any differences between loss estimates and actual loss

experience.

n) Insurance and investment contracts – classification

An insurance contract is a contract under which the Group accepts significant insurance risk from another

party (the policyholder) by agreeing to compensate the policyholder if a specified uncertain future event

(the insured event) adversely affects the policyholder. Insurance risk covers all risks except for financial

risks. All premiums have been received within the coverage of insurance contracts recognised as revenue

under “premiums written” account.

Investment contracts are those contracts which transfer financial risk without significant insurance risk.

Financial risk is the risk of a possible future change in a specified interest rate, financial instrument price,

commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index or other

variable, provided, that it is not specific to a party to the contract, in the case of a non-financial variable.

The insurance contracts and investment contracts are classified into three main categories, depending on

the duration.

Short-term insurance contracts

Short-term insurance contracts are health, personal accident and life insurance products protecting the

Group’s customers against cost of treatments in case of sickness, personal accident and short-duration life

contracts protecting the Group’s customers from the consequences of events (such as death and disability)

that would affect on the ability of the customer or his/her dependants to maintain their current level of

income. Guaranteed benefits paid on occurrence of the specified insurance event are either fixed or linked

to the extent of the economic loss suffered by the policyholder.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

17

3 Significant accounting policies (continued)

n) Insurance and investment contracts – classification (continued)

The Group also makes the intermediary of other insurance companies in Turkey for property and casualty

insurance products and private pension products and earns commission from intermediary operations.

Casualty insurance contracts protect the customers against the risk of causing harm to third parties as a

result of their legitimate activities. Property insurance contracts mainly compensate the customers for

damage suffered to their properties or for the value of property lost. Customers who undertake commercial

activities on their premises could also receive compensation for the loss of earnings caused by the inability

to use the insured properties in their business activities (business interruption cover). Private pension

products are saving products which the customer pays contribution on behalf of themselves as investment

contract. Those contracts are not recognised in the accompanying consolidated financial statements.

Long-term insurance contracts

These contracts insure events associated with human life (for example, death or survival) over a long

duration. Premiums are recognised as revenue when they become payable by the policyholders. Premiums

are shown before deduction of commission. Benefits are recorded as an expense when they are incurred.

A liability for contractual benefits that are expected to be incurred in the future is recorded when the

premiums are recognised. The liability is determined as the sum of the discounted value of the benefit

payments less the theoretical premiums that would be required to meet the benefits on the valuation

assumptions used.

All insurance benefit amounts are defined in TL or indexed to US Dollar or Euro. Net level premium

amount depends on the real age of the life assured. Upon request of the policyholder and against surrender

of the policy; the Group is obliged to purchase the insurance in the way specified in the policy for which

premiums have been paid at least for the stated term.

Investment contracts

The Group has saving life policies with regular and single premium payments. Premiums received for

such contracts are recognised directly as liability. These liabilities are increased by interest rate calculated

by the Group and are decreased by policy administration fees, mortality and surrender charges and any

withdrawals.

These contracts entitle the holders to a minimum guaranteed crediting rate per annum or, when higher, a

bonus rate declared by the Group from the eligible surplus available to date. The Group has an obligation

to eventually pay to contract holders at least 90% - 95% of the eligible surplus (i.e., all interest earned

from the assets backing these contracts) and holds 5% - 10 % as fee of administration of the operations.

The Group classifies these assets backing liabilities as financial assets at fair value through profit or loss,

available-for-sale financial assets, loans and receivables and held-to-maturity investments in the

accompanying consolidated financial statements. Since the Group is obliged to pay all eligible surplus

obtained from these assets to the policyholders, the Group recognises 90% - 95% (5%-10% is decreased

as policy administration fees) of eligible surplus as investment contract liabilities. In relation to the

unrealised gains and losses arising from the assets backing these contracts, the Group establishes a liability

equal to 90% - 95% of these net gains. Shareholders’ interest in the unrecognised gains and losses (equal

to 5% - 10%) is recognised in the equity.

Premium and benefit amounts are determined according to the future expectations of the policyholders

and the age of the life assured. Benefit amounts and premiums are indexed to hard currencies (US Dollar

or Euro) in order to make provision against the inflation.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

18

3 Significant accounting policies (continued)

n) Insurance and investment contracts – classification (continued)

Liability adequacy test

At each balance sheet date, asset-liability adequacy tests are performed to ensure the adequacy of contract

liabilities. In performing these tests, current best estimates of future cash flows are used. When estimating

future cash flows, the following parameters are used. Any deficiency is immediately assessed to test

whether if there is a need of establishing a provision for losses arising from liability adequacy tests.

-Future interest rate forecasts,

-Lapse and surrender rates of the existing contracts,

-Maturity rates,

-Average premium per insured

Long term life insurance contracts are measured based on assumptions set out at the inception of the

contract. When the liability adequacy test requires the adoption of new best estimate assumptions, such

assumptions are used for the subsequent measurement of these liabilities.

o) Deferred acquisition costs and deferred commission income

Commissions and other acquisition costs that vary with and are related to securing new contracts and

renewing existing insurance contracts are capitalised as deferred acquisition costs (“DAC”). Deferred

acquisition costs are amortised on a straight-line basis over the life of the contracts.

Deferred commission income is also calculated on a straight-line basis over the life of the contract based

on commission received from reinsurance firms.

p) Reserve for unearned premiums

Unearned premiums are those proportions of the premiums written in a period that relate to the period of

risk subsequent to the reporting date for all short-term insurance policies. In accordance with the

incumbent legislation on the computation of insurance contract liabilities, reserve for unearned premiums

set aside for unexpired risks as at the reporting dates, has been computed on daily pro-rata basis. The

change in the reserve for unearned premiums is recognised in the consolidated statement of

comprehensive income in the order that revenue is recognised over the period of risk.

Since the occurrence of the claim is directly correlated with the seasons, for short-term insurance contracts

especially in health branch, the Group reassesses the reserve for unearned premiums on the basis of the

expected timing of incurred claims and benefits in a year and makes related adjustment on reserve for

unearned premiums considering the inception and maturity dates of the policies’ coverage. The Group

also adjusts reserve for unearned premiums to reflect the effect of medical inflation on reserve for

unearned premiums. Since the medical inflation is mainly determined by the change in TTB cofactor by

the Turkish Medical Association and announced once in a year at the beginning of the year, distribution

of the claim over the policy period is not parallel to the earning schedule of the premiums. Those analyses

are made on policy basis. Accordingly as at and for the year ended December 31, 2018, the Group adjusted

reserve for unearned premiums by TL 19,654,243 (December 31, 2017: TL 9,024,180).

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

19

3 Significant accounting policies (continued)

q) Provision for outstanding claims / IBNR

Outstanding claims reserve represents the estimate of the total reported costs of notified claims on an

individual case basis at the reporting date as well as the corresponding handling costs. A provision for

claims incurred but not reported (“IBNR”) is also established as described below. In the accompanying

consolidated financial statements, provision for claims is presented by netting of amounts recoverable

from reinsurers. Estimates have to be made both for the expected ultimate cost of claims reported at the

reporting date and for the expected ultimate cost of IBNR claims at the reporting date. It can take a

significant period of time before the ultimate claims cost can be established with certainty. The primary

technique adopted by management in estimating the cost of IBNR claims, is that of using past claim

settlement trends to predict future claims settlement trends. At each reporting date, prior year claims

estimates are reassessed for adequacy and changes are made to the provision. In addition to that, the Group

also reassesses its notified claims provision at each reporting date on each claim file basis. General

insurance claims provisions are not discounted for the time value of money.

r) Life mathematical provisions

Life mathematical provisions are recorded to reflect the liability of the Group against the policyholders

for long-term life policies and calculated as the difference between the net present values of premiums

collected in return of the risk covered by the Group and the liabilities to policyholders. Life mathematical

provisions are the sum of the remainder of collected premiums. Life mathematical provisions are

computed on the basis of actuarial mortality assumptions as approved by the Turkish Treasury, which are

applicable for Turkish insurance companies.

s) Reinsurance contracts held

Contracts entered into by the Group with reinsurers under which the Group is compensated for losses on

one or more contracts issued by the Group, and that meet the classification requirements for insurance

contracts are classified as reinsurance contracts held.

The benefits to which the Group is entitled under its reinsurance contracts held are recognised as

reinsurance assets. These assets consist of short-term balances due from reinsurers, as well as longer term

receivables that are dependent on the expected claims and benefits arising under the related reinsured

insurance contracts. Amounts recoverable from or due to reinsurers are measured consistently with the

amounts associated with the reinsured insurance contracts and in accordance with the terms of each

reinsurance contract. Reinsurance liabilities are primarily premiums payable for reinsurance contracts and

are recognised as an expense when due.

Unearned reinsurance premiums are those proportions of premiums written in a year that relate to periods

of risk after the reporting date. Unearned reinsurance premiums are deferred over the term of the

underlying direct insurance policies for risks-attaching contracts and over the term of the reinsurance

contract for losses occurring contracts.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

20

3 Significant accounting policies (continued)

t) Employee benefits

Reserve for employee severance indemnity

Reserve for employee severance indemnity represents the present value of the estimated future probable

obligation of the Group arising from the retirement of the employees and calculated in accordance with

the Turkish Labour Law. It is computed and reflected in the consolidated financial statements on an

accrual basis as it is earned by serving employees. The computation of the liabilities is based upon the

retirement pay ceiling announced by the Government. The ceiling amounts are TL 5,434 and TL 4,732 at

December 31, 2018 and 2017 respectively.

IAS 19 – Employee benefits requires actuarial valuation methods to be developed to estimate the

enterprise’s obligation under defined benefit plans. The principal statistical assumptions used in the

calculation of the total liability in the accompanying consolidated financial statements As at December

31, 2018 and 2017 are as follows:

December 31, 2018 December 31, 2017

Discount rate 3.91% 4.67%

Expected rate of salary/limit increase 28.50% 7.00%

Turnover rate to estimate the probability of retirement 9.82% 15.33%

In accordance with the revision of IAS 19, effective starting from January 1, 2013, the Group recognized

actuarial gains and losses arising on the defined benefit obligations in other comprehensive income.

Short-term employee benefits

The Group has recorded provision for undiscounted short-term employee benefits accrued during the

period as per services rendered in compliance with IAS 19 in the accompanying consolidated financial

statements.

u) Provisions

A provision is recognised if, as a result of a past event, the Group has a present legal or constructive

obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be

required to settle the obligation. Provisions are determined by discounting the expected future cash flows

at a pre-tax rate that reflects current market assessments of the time value of money and, where

appropriate, the risks specific to the liability. Provisions are reviewed at each reporting date and adjusted

to reflect the current best estimate. Future operating costs are not provided for.

Where the effect of the time value of money is material, the amount of a provision is the present value of

the expenditures expected to be required to settle the obligation. When discounting is used, the increase

in provision reflecting the passage of time is recognised as finance cost.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

21

3 Significant accounting policies (continued)

v) Taxes on income

Income tax expense comprises current and deferred taxes. In case where gains/losses resulting from the

subsequent measurement of the assets or liabilities are recognised in profit or loss, then the related current

and/or deferred tax effects are also recognised in profit or loss. On the other hand, if such gains/losses are

recognised as an item under equity, then the related current and/or deferred tax effects are also recognised

directly in the equity.

Current taxes

Statutory income is subject to corporate tax at 20%. “Law Regarding Amendments on Certain Tax Laws

and Other Laws” as prepared by the Turkish Republic Ministry of Finance is came into effect by the

issuance in the December 5, 2017 dated Official Gazette. This new Law offers temporarily increase in

corporate tax rate to 22% for a period of 3 years including 2018, 2019 and 2020 and changes in some

other taxes. Council of the Ministers are entitled to decrease this rate to 20% at any time.

This rate is applied to accounting income modified for certain exemptions (like dividend income) and

deductions (like investment incentives), and additions for certain non-tax deductible expenses and

allowances for tax purposes. If there is no dividend distribution planned, no further tax charges are made.

Dividends paid to the resident institutions and the institutions working through local offices or

representatives are not subject to withholding tax. Withholding tax rate on the dividend payments other

than the ones paid to the non-resident institutions generating income in Turkey through their operations

or permanent representatives and the resident institutions is 15%. In applying the withholding tax rates to

the non-resident institutions and the individuals, the withholding tax rates covered in the related Double

Tax Treaty Agreements are taken into account. Appropriation of the retained earnings to capital is not

considered as profit distribution and therefore is not subject to withholding tax.

The prepaid taxes are calculated and paid at the rates valid for the earnings of the related years. The

payments can be deducted from the annual corporate tax calculated for the whole year earnings.

In accordance with the tax legislation, tax losses can be carried forward to offset against future taxable

income for up to five years. Tax losses cannot be carried back to offset profits from previous periods.

In Turkey, there is no procedure for a final and definite agreement on tax assessments. Companies file

their tax returns by the end of the 25th day of the fourth month following the close of the accounting period

to which they relate. Tax returns are open for five years from the beginning of the year that follows the

date of filing during which time the tax authorities have the right to audit tax returns, and the related

accounting records, and may issue re-assessments based on their findings.

Deferred taxes

Deferred tax assets and liabilities are recognised on all taxable temporary differences arising between the

carrying values of assets and liabilities in the financial statements and their corresponding balances

considered in the calculation of the tax base, except for the differences not deductible for tax purposes

and initial recognition of assets and liabilities which affect neither accounting nor taxable profit.

The deferred tax assets and liabilities are reported as net in the accompanying consolidated financial

statements if, and only if, the Group has a legally enforceable right to set off current tax assets against

current tax liabilities and the deferred tax assets and deferred tax liabilities are income taxes of same

taxable entity and relate to income taxes levied by the same taxation authority.

A deferred tax asset is recognised for unused tax losses, tax credits and deductible temporary differences

to the extent that it is probable that future taxable profits will be available against which they can be

utilised. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no

longer probable that the related tax benefit will be realised.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

22

3 Significant accounting policies (continued)

v) Taxes on income (continued)

Transfer pricing

In Turkey, the transfer pricing provisions have been stated under the Article 13 of Corporate Tax Law with

the heading of “disguised profit distribution via transfer pricing”. The General Communiqué on disguised

profit distribution via Transfer Pricing, dated November 18, 2007 sets details about implementation.

If a taxpayer enters into transactions regarding sale or purchase of goods and services with related parties,

where the prices are not set in accordance with arm’s length principle, then related profits are considered to

be distributed in a disguised manner through transfer pricing. Such disguised profit distributions through

transfer pricing are not accepted as tax deductible for corporate income tax purposes.

w) Related parties

For the purpose of the accompanying consolidated financial statements, shareholders, key management

personnel and board members, in each case together with their families and companies controlled by or

affiliated with them, and associated companies are considered and referred to as related parties.

x) The new standards, amendments and interpretations

The accounting policies adopted in preparation of the consolidated financial statements as at

December 31, 2018 are consistent with those of the previous financial year, except for the adoption of

new and amended IFRS and IFRIC interpretations effective as of January 1, 2018. The effects of these

standards and interpretations on the Group’s financial position and performance have been disclosed in

the related paragraphs.

i) The new standards, amendments and interpretations which are effective as at

January 1, 2018 are as follows:

IFRS 15 Revenue from Contracts with Customers

The IASB issued IFRS 15 Revenue from Contracts with Customers. The new five-step model in the

standard provides the recognition and measurement requirements of revenue. The standard applies to

revenue from contracts with customers and provides a model for the sale of some non-financial assets that

are not an output of the entity’s ordinary activities (e.g., the sale of property, plant and equipment or

intangibles). IFRS 15 for annual periods beginning on or after January 1, 2018.

The Company has postponed the transition to TFRS 15 on January 1, 2021 in accordance with the

“Circular on Insurance Date of Insurance and Pension Companies RS dated October 23, 2018 and

numbered 2018/4 issued by the Ministry of Treasury and Finance.

IFRS 9 Financial Instruments

In July 2014, the IASB issued the final version of IFRS 9 Financial Instruments. The final version of

IFRS 9 brings together all three aspects of the accounting for financial instruments project: classification

and measurement, impairment and hedge accounting. IFRS 9 is built on a single classification and

measurement approach for financial assets that reflects the business model in which they are managed

and their cash flow characteristics. Built upon this is a forward-looking expected credit loss model that

will result in more timely recognition of loan losses and is a single model that is applicable to all financial

instruments subject to impairment accounting. IFRS 9 addresses the so-called ‘own credit’ issue, whereby

banks and others book gains through profit or loss as a result of the value of their own debt falling due to

a decrease in credit worthiness when they have elected to measure that debt at fair value. IFRS9 also

includes an improved hedge accounting model to better link the economics of risk management with its

accounting treatment. IFRS 9 is effective for annual periods beginning on or after January 1, 2018. Until

IFRS 17 is effective, the Group will benefit from temporary exemption clauses for IFRS 9.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

23

3 Significant accounting policies (continued)

x) The new standards, amendments and interpretations (continued)

IFRS 4 Insurance Contracts (Amendments)

In September 2016, the IASB issued amendments to IFRS 4 Insurance Contracts. The amendments

introduce two approaches: an overlay approach and a deferral approach. The amended Standard will:

a. give all companies that issue insurance contracts the option to recognise in other comprehensive

income, rather than profit or loss, the volatility that could arise when IFRS 9 Financial instruments is

applied before the new insurance contracts Standard is issued; and

b. give companies whose activities are predominantly connected with insurance an optional temporary

exemption from applying IFRS 9 Financial instruments until 2021. The entities that defer the application

of IFRS 9 will continue to apply the existing financial instruments Standard-IAS 39.

These amendments are applied for annual periods beginning on or after January 1, 2018. The amendments

did not have a significant impact on the financial position or performance of the Group.

IFRIC 22 Foreign Currency Transactions and Advance Consideration

The interpretation clarifies the accounting for transactions that include the receipt or payment of advance

consideration in a foreign currency.

The Interpretation states that the date of the transaction for the purpose of determining the exchange rate

to use on initial recognition of the related asset, expense or income is the date on which an entity initially

recognises the non-monetary asset or non-monetary liability arising from the payment or receipt of

advance consideration. An entity is not required to apply this Interpretation to income taxes; or insurance

contracts (including reinsurance contracts) it issues or reinsurance contracts that it holds.

The interpretation is effective for annual reporting periods beginning on or after January 1, 2018. The

Group is in the process of assessing the impact of the interpretation on the financial position or

performance of the Group.

IFRS 2 Classification and Measurement of Share-based Payment Transactions (Amendments)

The IASB issued amendments to IFRS 2 Share-based Payment, clarifying how to account for certain types

of share-based payment transactions. The amendments, provide requirements on the accounting for:

(a) the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based

payments;

(b) share-based payment transactions with a net settlement feature for withholding tax obligations;

and

(c) a modification to the terms and conditions of a share-based payment that changes the

classification of the transaction from cash-settled to equity-settled.

These amendments are applied for annual periods beginning on or after January 1, 2018. The amendments

did not have a significant impact on the financial position or performance of the Group.

IAS 40 Investment Property: Transfers of Investment Property (Amendments)

The IASB issued amendments to IAS 40 'Investment Property '. The amendments state that a change in use

occurs when the property meets, or ceases to meet, the definition of investment property and there is

evidence of the change in use. These amendments are applied for annual periods beginning on or after

January 1, 2018. The amendments did not have a significant impact on the financial position or performance

of the Group.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

24

3 Significant accounting policies (continued)

x) The new standards, amendments and interpretations (continued)

Annual Improvements to IFRSs - 2014-2016 Cycle

The IASB issued Annual Improvements to IFRS Standards 2014–2016 Cycle, amending the following

standards:

IAS 28 Investments in Associates and Joint Ventures: This amendment clarifies that the election to

measure an investment in an associate or a joint venture held by, or indirectly through, a venture capital

organisation or other qualifying entity at fair value through profit or loss applying IFRS 9 Financial

Instruments is available for each associate or joint venture, at the initial recognition of the associate or

joint venture. These amendments are applied for annual periods beginning on or after January 1, 2018.

The amendments did not have a significant impact on the financial position or performance of the Group.

ii) Standards issued but not yet effective and not early adopted

Standards, interpretations and amendments that are issued but not yet effective at the reporting date are

as follows. The Group plans to apply the new standards and interpretations when they become effective.

IFRS 16 Leases

The IASB has published a new standard, IFRS 16 'Leases'. Lessor accounting however remains largely

unchanged and the distinction between operating and finance leases is retained. IFRS 16 supersedes IAS

17 'Leases' and related interpretations and is effective for periods beginning on or after January 1, 2019,

with earlier adoption permitted.

Lessees have recognition exemptions to applying this standard in case of short-term leases (i.e., leases

with a lease term of 12 months or less) and leases of ’low-value’ assets (e.g., personal computers, office

equipment, etc.). At the commencement date of a lease, a lessee measures the lease liability at the present

value of the lease payments that are not paid at that date (i.e., the lease liability), at the same date

recognises an asset representing the right to use the underlying asset (i.e., the right-of-use asset) and

depreciates it during the lease term. The lease payments shall be discounted using the interest rate implicit

in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the lessee

shall use the lessee’s incremental borrowing rate. Lessees are required to recognise the interest expense

on the lease liability and the depreciation expense on the right-of-use asset separately.

Lessees are required to remeasure the lease liability upon the occurrence of certain events (e.g. a change

in the lease term, a change in future lease payments resulting from a change in an index or rate). Under

these circumstances, the lessee recognises the amount of the remeasurement of the lease liability as an

adjustment to the right-of-use asset. The Group does not expect that this standard will have a significant

impact on the financial position or performance of the Group.

Amendments to IAS 28 Investments in Associates and Joint Ventures (Amendments)

In October 2017, the IASB issued amendments to IAS 28 Investments in Associates and Joint Ventures.

The amendments clarify that a company applies IFRS 9 Financial Instruments to long-term interests in an

associate or joint venture that form part of the net investment in the associate or joint venture.

IFRS 9 Financial Instruments excludes interests in associates and joint ventures accounted for in

accordance with IAS 28 Investments in Associates and Joint Ventures. In this amendment the IASB

clarified that the exclusion in IFRS 9 applies only to interests a company accounts for using the equity

method. A company applies IFRS 9 to other interests in associates and joint ventures, including long-term

interests to which the equity method is not applied and that, in substance, form part of the net investment

in those associates and joint ventures.

The amendments are effective for annual periods beginning on or after January 1, 2019 with early

application permitted. The Group does not expect that this standard will have a significant impact on the

financial position or performance of the Group.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

25

3 Significant accounting policies (continued)

x) The new standards, amendments and interpretations (continued)

IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and its Associate or Joint

Venture (Amendments)

In December 2015, the IASB postponed the effective date of this amendment indefinitely pending the

outcome of its research project on the equity method of accounting. Early application of the amendments

is still permitted. The Group will assess the impact of the amendments after the standards are finalized.

IFRIC 23 Uncertainty over Income Tax Treatments

The interpretation clarifies how to apply the recognition and measurement requirements in “IAS 12

Income Taxes” when there is uncertainty over income tax treatments.

When there is uncertainty over income tax treatments, the interpretation addresses:

(a) whether an entity considers uncertain tax treatments separately;

(b) the assumptions an entity makes about the examination of tax treatments by taxation authorities;

(c) how an entity determines taxable profit (tax loss), tax bases, unused tax losses, unused tax credits

and tax rates; and

(d) how an entity considers changes in facts and circumstances.

An entity shall apply this Interpretation for annual reporting periods beginning on or after January 1, 2019.

Earlier application is permitted. If an entity applies this Interpretation for an earlier period, it shall disclose

that fact. On initial application, an entity shall apply the interpretation either retrospectively applying IAS

8, or retrospectively with the cumulative effect of initially applying the Interpretation recognised at the

date of initial application. The Group is in the process of assessing the impact of the amendments on

financial position or performance of the Group.

4 Critical accounting estimates and judgments in applying accounting policies

The notes given in this section are provided to addition/supplement the commentary on the Note 5 –

Management of insurance risk and Note 6 – Management of financial risk.

The preparation of the consolidated financial statements requires management to make judgments,

estimates and assumptions that affect the application of accounting policies and the reported amounts of

assets, liabilities, income and expenses. Actual results may differ from these estimates.

Ultimate liability arising from claims made under insurance contracts

The estimation of the ultimate liability arising from claims made under insurance contracts is executed

depending on different assumptions. Mortality tables CSO1953-58, CSO 80 (Male-Female), CSO 2001

(Male-Female) approved by the Turkish Treasury are used to estimate the ultimate liability arising from

life insurance policies. For estimating the risk of critical illness, the Critical Illness Rating Tables which

are recommended by leader treaty reinsurer are used.

Estimate of future benefit payments and premiums arising from long-term insurance contracts

For estimation of future benefit and premium payments, four parameters have significant impacts:

i) The lapse and surrender rates: These estimated rates are derived from past experience. In its estimation,

the Group also takes into consideration the economic crisis or positive economic developments that will

affect the rates either in a positive or a negative way.

ii) Number of deaths: While estimating number of deaths, the historical mortality experiences are used.

iii) Future investment income: This estimate is based on current market returns as well as expectations

about future economic and financial developments.

iv) Average premium per insured: The assumption is based on historical trends in average premium

amounts per insured and economical expectations that may affect the average premium amount.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

26

5 Management of insurance risk

Insurance risk is the likelihood that an insured event will occur, requiring the insurer to pay a claim. By

the very nature of an insurance contact, the risk is random and therefore unpredictable.

For a portfolio of insurance contracts where the theory of the probability is applied to pricing and

provisioning, the principal risk that the Group faces under its insurance contracts is that the actual claim

and benefit payments exceed carrying amount of the insured liabilities. These could occur because the

frequency or severity of claims and benefits are greater than estimated. Insurance events are random and

the actual number and amount of claims and benefits will vary from year to year from the estimate

established using statistical techniques.

Experience shows that the larger the portfolio of similar insurance contracts, the smaller the relative

variability about the expected outcome will be. In addition, a more diversified portfolio is likely to be

affected across the board by a change in any subset of portfolio.

The Group has developed its insurance underwriting strategy to diversify the type of insurance risks

accepted and within each of these categories to achieve a sufficiently large population of risks to reduce

the variability of the expected outcome.

Pricing policies

The pricing policies and principles of the Group are as follows:

i) While determining risk premiums, the amount of expected losses are considered and premium

limits are determined accordingly.

ii) During the study of pricing activities as a part of developing a new product, working of relevant

units together within the Group is maintained by considering the needs of the customers and

competition in the market.

iii) It is aimed to achieve profitability in product basis and providing continuity.

iv) Results of the pricing studies are compared with the prices of the competitors and international

pricing cases, if observable.

The Group accepts insurance risk in health, life insurance, and personal accident branches. The Group

also engages in other non-life branches through its intermediary operations of its subsidiary of which

financial statements are consolidated in the accompanying consolidated financial statements. On the other

hand, since the Group does not underwrite policies in those branches, they are not included in the

accompanying consolidated financial statements.

Health contracts

In health branch, the Group underwrites both individual and corporate policies under which insured

medical expenses are compensated by the Group.

In individual segment, the Group offers a wide-range of products and extensive network of contracted

service providers and detailed policy coverage to its individual customers which includes different

indemnities and guarantees containing inpatient, outpatient, physician, birth-maternity, treatments in

abroad, doctor and medicine, laboratory and screening, physical treatment, check-up, domestic and

international travels and critical illnesses warranties.

The Company offers optional coverage to its customers enabling to establish a product by including a

variety of coverages in line with the customers’ needs. The unique product offered in the market, requires

the Company to assess the risk arising due to flexible type and based on the needs accordingly and

accurately. This brings Company to face with high risk due to risk selection issue underlying in the nature

of the product.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

27

5 Management of insurance risk (continued)

Health contracts (continued)

In corporate segment, the Group provides tailor-made products which are designed in accordance with

the requests and needs of the corporate by considering the demographic distribution of the corporate

employees. The Group offers a wide range of elastic products and extensive network of contracted service

providers and detailed policy coverage.

The risk for the insurance contracts is related with the fact that the possibility of the insurance incident to

occur and the damage amounts stemming from this certain incident is unknown due to the very nature of

the insurance contracts, the respective risk is coincidental and hence cannot be foreseen thoroughly. The

Group manages the respective risks with policy construction strategies and reassurance contracts where

there are parties in all branches. Pricing by the Group is made based on the statistical analysis, previous

data and morbidity and mortality tables with regards to the respective product.

Considering the guarantee types provided by the Group, the numbers and quantitative distribution can be

observed in the table below. The Group management believes that the numbers and the quantitative

distribution are sufficient.

Risk contracts in life and personal accident

Meşe Accident: While death due to the accident is the main guarantee, other guarantees such as medical

treatment costs for the permanent disability due to the accident, permanent disability due to illness, and

guarantees for death due to the accidents in public transportation are also provided under Acıbadem

Accident.

Acıbadem School: It is designed so that the child can continue his/her education in the event that the

person who is taking care of the education costs of the child dies. Insurance duration is determined with

consideration of the child’s education duration and insurance guarantee is determined with consideration

of education costs which might emerge during this period. Death indemnity can be presented as stable or

in annually decreasing amounts during the insurance period depending on the request of the insurer.

Within the framework of this product, disability guarantee due to the accident can also be provided.

Goknar Annual Life Insurance: In this product whose insurance duration is one year, the death risk of the

insurer in one year is taken under indemnity. Indemnity and premiums can be selected as Turkish Lira,

US Dollar and Euro in the policy.

Acıbadem Credit: It is designed for the payment of bank loan taken for house purchases in the event that

the person who got the credit dies and for the rest of the family not to suffer. Insurance period is

determined with consideration of the credit period and the insurance indemnity is determined with the

consideration of loan amount to be paid during this period. Death indemnity can be presented as stable or

in annually decreasing amounts during the insurance period depending on the request of the insured.

Within the framework of this product, disability guarantee due to the accident can also be provided.

Reinsurance contracts

Reinsurance contracts are the contracts which are signed by the Group for the losses which might stem

from one or more insurance contracts, and which put into force by the Group and reinsurance company,

whose costs have been paid and which meets all the requirements to be categorised as insurance contracts.

As at December 31, 2018, the Group has proportional and catastrophic (“Cat XL”) reinsurance agreements

with Caisse Centrale de Réassurance (CCR Re) in life, personal accident and critical illnesses branches.

The Group signed excess of loss non-proportional reinsurance contracts in order to protect itself against

catastrophic damages in health branch. In CAT XL non-proportional reinsurance contracts signed by the

Group in health branch, the reinsurer company is HCC International Insurance Company PLC (“HCC”).

In excess of loss non-proportional reinsurance contract signed by the Group in health branch, the reinsurer

company is Caisse Centrale de Réassurance (CCR Re).

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

28

5 Management of insurance risk (continued)

Reinsurance companies

Reinsurance companies, providing reinsurance protection against health, life, personal accident and

critical illness insurance risks are the one of the most important service providers of the Group. The

decisive criteria for the relationship with reinsurers are as follows:

i) Financial strength,

ii) Long-term relationship approach,

iii) Competitive prices,

iv) Capacity provided for facultative and un-proportional (catastrophic) reinsurance contracts,

v) Opportunities and information provided in risk assessment process, product development,

trainings, information about new developments in the sector and etc.

Performance of the reinsurance companies in treaty agreements is evaluated for each year by considering

the payment performance of the reinsurers for the claims paid and other due payables to the Group.

Performance of the reinsurance companies in facultative agreements is evaluated by considering capacity

provided to the Group, speed in operational reinsurance transactions, and technical and market

information provided to the Group. In case where the performance of the reinsurer is not assessed as

adequate, the Group decides on to agree with alternative reinsurance companies.

The latest credit rating grades of these companies can be seen in the table below.

Company

Standard & Poors AM Best

Grade Outlook Grade Outlook

HCC AA Stable A+ Stable

CCR Re AA Stable A+ Stable

Insurance risk accepted by the Group in accordance with their total amounts and numbers are presented

in the below table. The Group management believes that the distribution of the insurance risk in terms of

their total amounts and numbers are satisfactory.

December 31, 2018 December 31, 2017

Insurance risk (TL) Number Insurance risk (TL) Number

Death due to accident 3,824,124,778 71,704 2,865,898,728 63,377

Disability due to accident 3,798,552,843 71,910 3,211,918,711 91,105

Death 2,717,587,398 96,783 3,618,188,009 137,160

Disability due to accident (Earthquake included) 2,617,912,378 25,308 2,049,385,926 27,171

Death due to accident (Earthquake included) 2,091,051,089 33,416 2,097,008,426 36,284

Disability due to illness 1,798,446,118 15,594 1,516,306,190 15,654

Treatment costs due to accident 109,814,785 8,240 29,234,983 7,946

Critical illness 57,333,388 1,017 50,715,038 1,023

Daily hospital benefit due to accident 50 1 3,900 26

Broken/Burn - - 130,000 26

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

29

6 Management of financial risk

Introduction and overview

This note presents information about the Group’s exposure to each of the below risks, the Group’s

objectives, policies and processes for measuring and managing financial risk, and the Group’s

management of capital. The Group has exposure to the following risks through its financial assets,

financial liabilities, reinsurance assets and insurance liabilities. The most significant components of these

financial risks are:

credit risk

liquidity risk

market risk

The Board of Directors has overall responsibility for the establishment and oversight of the Group’s risk

management framework. The Board of Directors monitors the effectiveness of the risk management

system through the Group’s internal audit and internal control functions. The Group’s finance and

management reporting department is responsible from monitoring and management of financial risk that

the Group faces, preparing financial risk analysis of the Group.

The Group’s risk management policies are established to identify and analyse the risks faced by the Group,

to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management

policies and systems are reviewed regularly to reflect changes in market conditions, products and services

offered. The Group, through its training and management standards and procedures, aims to develop a

disciplined and constructive control environment, in which all employees understand their roles and

obligations.

Credit risk

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument

fails to meet its contractual obligations. Key areas where the Group is exposed to credit risk are:

cash and cash equivalents (except for cash on hand),

financial assets at fair value through profit or loss,

available-for-sale financial assets,

held to maturity investment securities,

loans and receivables,

reinsurers’ share of insurance liabilities,

amounts due from reinsurers in respect of claims already paid and commissions,

amounts due from insurance contract holders,

amounts due from insurance intermediaries, and

other receivables.

Reinsurance is utilised to manage insurance risk. This does not, however, discharge the Group’s liability

as primary insurer. If a reinsurer fails to pay a claim for any reason, the Group remains liable for the

payment to the policyholders. The creditworthiness of reinsurers is considered on an annual basis by

reviewing their financial strength prior to finalisation of the contract.

The exposure to individual counterparties is also managed by other mechanisms, such as the right of offset

where counterparties are both debtors and creditors of the Group. Exposures to individual policyholders

and groups of policyholders are collected within the ongoing monitoring of the controls associated with

regulatory solvency.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

30

6 Management of financial risk (continued)

Credit risk (continued)

The carrying amount of assets represents the maximum credit exposure. As at December 31, 2018 and

2017, the maximum exposure to credit risk is:

Carrying amount

December 31, 2018 December 31, 2017

Financial assets owned by the Group (Note 8) 617,547,596 507,771,674

Premium and other insurance receivables and due from ,insurance and

reinsurance companies (Note 10,11) 214,933,212 152,557,735

Cash and cash equivalents (Note 7) 125,549,968 109,985,712

Income accruals (Note 13) 20,497,437 12,239,155

Fin. assets backing inv. contract liabilities (Note 8) 19,449,935 21,472,121

Claims provision, reinsurers’ share (Note 22) 8,080,711 7,404,983

Advances given (Note 13) 754,614 244,874

Miscellaneous receivables (Note 13) 285,809 514,066

Cash at banks pledged in favour of the Turkish Treasury (Note 8) 142,715 12,931,963

Deposits given (Note 13) 53,642 48,192

Due from related parties (Note 13) - 44,676

Total 1,007,295,638 825,215,151

Since the Group operates only in Turkey, geographic concentration of the maximum exposure to credit

risk for premium and other insurance receivables at the reporting date is domestic. The Group’s securities

portfolio mainly consists of TL and foreign currency (FC) denominated government bonds, treasury bills

and Eurobonds issued by the Turkish Government. Those securities are accepted as having low credit

risk. The Group also has private sector corporate bonds of some private Turkish banks and industrial

companies with high credit ratings. The Group only invests in the corporate bonds of the private sector

companies which accomplish certain financial criteria set by the Group.

As at December 31, 2018 and 2017, the aging of premium and other insurance receivables and due from

reinsurance companies is:

December 31, 2018 December 31, 2017

Gross Impairment Gross Impairment

Not past due 157,359,807 - 130,837,422 -

Past due 0-30 days 52,622,344 - 20,934,608 (1,390)

Past due 31-60 days 852,388 (178,979) 1,084,766 (297,671)

Past due 61-180 days 2,613,366 (140,574) 970,561 (970,561)

Past due 180-365 days 1,620,602 (44,091) 22,682 (22,682)

More than one year 7,384,214 (7,155,866) 7,120,733 (7,120,733)

Total 222,452,722 (7,519,510) 160,970,772 (8,413,037)

For the years ended December 31, 2018 and 2017, the movements in the allowance for impairment in

premium and other insurance receivables and due from insurance and reinsurance companies is as follows:

December 31, 2018 December 31, 2017

Balance at the beginning of the year (Note 10,11) (8,413,037)

(8,879,388)

Collections during the year 1,051,786 218,861

Impairment loss recognised during the year (158,259)

247,490

Balance at the end of the year (Note 10,11) (7,519,510)

(8,413,037)

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

31

6 Management of financial risk (continued)

Credit risk (continued)

The Group cancels the policies where premiums are accrued but not collected within a certain period of

time, and deducts them from the gross premiums and from the premium and other insurance receivables.

Collaterals obtained for receivables are as follows:

December 31, 2018 December 31, 2017

Cash 1,047,016 1,307,136

Letter of guarantee 524,000 286,000

Guarantee notes 44,000 44,000

Immovable 20,250 20,250

Blocked deposits 19,565 19,565

Guarantee cheques 11,640 11,640

Total 1,666,471 1,688,591

Liquidity risk

Liquidity risk is the risk that the Group will encounter difficulty in meeting obligations of its financial

liabilities. The Group’s approach to managing liquidity is to ensure, as far as possible, that it will always

have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions,

without incurring unacceptable losses or risking damage to the Group’s reputation. The Group monitors

its liquidity position on a daily basis, which assists it in monitoring cash flow requirements and optimising

its cash return on investments. Typically the Group ensures that it has sufficient liquid assets to meet

expected operational expenses including the servicing of financial obligations; this excludes the potential

impact of extreme circumstances that cannot reasonably be predicted. The following table provides an

analysis of monetary liabilities of the Group into relevant maturity groupings based on the remaining

periods to repayments. The figures show the undiscounted cash flows of the Group’s monetary liabilities

on the basis of their earliest possible contractual maturity.

December 31, 2018

Carrying

amounts

Contractual

amounts

Up to 1

month

1 to 3

month

3 to 6

months

6 to 12

months

Over

1 year

Non-derivative financial liabilities

Financial liabilities 170,807 (170,807) (170,807) - - - -

Insurance liabilities including the

payables to medical networks

148,555,775

(148,555,775)

(65,381,386)

(83,174,389) - - -

Investment contract liabilities 11,460,198 (11,460,198) (213,959) (560,617) (448,846) (1,299,440) (8,937,336)

Outstanding claims provision 85,812,860 (85,812,860) (14,765,434) (27,274,886) (41,639,095) (452,095) (1,681,350)

Other prov. and employee benefits 45,493,596 (45,493,596) (1,097,444) (21,059,188) (4,963,816) (14,864,454) (3,508,694)

Other liabilities 18,123,768 (18,123,768) (14,368,036) (3,755,732) - - -

Total 309,617,004 (309,617,004) (95,997,066) (135,824,812) (47,051,757) (16,615,989) (14,127,380)

December 31, 2017

Carrying

amounts

Contractual

amounts

Up to 1

month 1 to 3 month

3 to 6

months

6 to 12

months

Over

1 year

Non-derivative financial liabilities Financial liabilities 304,066 (304,066) (304,066) - - - -

Insurance liabilities including the

payables to medical networks

139,907,149

(139,907,149)

(71,359,504)

(68,547,645) - - -

Investment contract liabilities 13,549,664 (13,549,664) (94,769) (811,691) (747,113) (928,596) (10,967,495)

Outstanding claims provision 47,163,754 (47,163,754) (10,001,981) (17,666,894) (17,125,529) (2,369,350) -

Other prov. and employee benefits 32,399,951 (32,399,951) (4,104,843) (12,622,703) (3,324,267) (10,412,413) (1,935,725)

Other liabilities 48,227,980 (48,227,980) (43,279,876) (4,948,104) - - -

Income taxes payable 2,868,342 (2,868,342) (2,868,342) - - -

Total 284,420,906 (284,420,906) (129,145,039) (107,465,379) (21,196,909) (13,710,359) (12,903,220)

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

32

6 Management of financial risk (continued)

Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates and interest rates will

affect the Group’s income or the value of its holdings of financial instruments. The objective of market

risk management is to manage and control market risk exposures within acceptable parameters, while

optimising the return on risk.

Currency risk

The Group is exposed to currency risk mainly on investment contracts, underwriting and reinsurance

activities denominated in US Dollar and Euro other than TL which is the functional currency of the Group.

The Group also invests in financial assets denominated in the same currencies in relation to the insurance

and investment contract liabilities.

The Group is long in on-balance sheet position in US Dollar and in Euro. The Group uses derivative

financial instruments actively in order to manage currency position resulting from regular operations. It

is not possible to match foreign currency denominated financial assets with foreign currency denominated

investment contract liabilities on an ongoing basis, since the policyholders have right to withdraw their

savings at any time after completing a certain time as defined in the regulations after inception of the

contracts. The Group’s exposure to foreign currency position was as follows based on notional amounts

(TL equivalents).

December 31, 2018 US Dollar Euro Total

Cash and cash equivalents 5 75,112,203 75,112,208

Investment securities 563,623,161 2,904,834 566,527,995

Premiums and other insurance receivables 595,446 (2,352,913) (1,757,467)

Other receivables 1,762,253 - 1,762,253

Total foreign currency denominated monetary assets 565,980,865 75,664,124 641,644,990

Due to reinsurance companies - 103,301 103,301

Outstanding claims provision 1,980,606 (4,011,716) (2,031,110)

Investment contract liabilities 4,322,740 290,755 4,613,495

Other liabilities 148,961 9,066 158,027

Total foreign currency denominated monetary liabilities 6,452,307 (3,608,594) 2,843,713

Net on-balance sheet position 559,528,558 79,272,717 638,801,276

Net off-balance sheet position (559,794,718) (76,115,270) (635,909,989)

Net long/(short) position (266,160) 3,157,447 2,891,286

December 31, 2017 US Dollar Euro Total

Cash and cash equivalents 8,433,314 21,908,218 30,341,532

Investment securities 405,023,241 18,106,896 423,130,137

Premiums and other insurance receivables 537,448 3,542,222 4,079,670

Other receivables 14,435 - 14,435

Total foreign currency denominated monetary assets 414,008,438 43,557,336 457,565,774

Due to reinsurance companies 534,902 636,883 1,171,785

Outstanding claims provision 1,969,003 102,077 2,071,080

Investment contract liabilities 4,676,134 289,302 4,965,436

Other liabilities 260,448 54,581 315,029

Total foreign currency denominated monetary liabilities 7,440,487 1,082,843 8,523,330

Net on-balance sheet position 406,567,951 42,474,493 449,042,444

Net off-balance sheet position (406,616,583) (43,851,853) (450,468,436)

Net long/(short) position (48,632) (1,377,360) (1,425,992)

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

33

6 Management of financial risk (continued)

Market risk (continued)

Currency risk (continued)

10% devaluation of the TL against the following currencies as at December 31, 2018 and 2017 would

have increased equity and profit or loss (without tax effects) by the amounts shown below. This analysis

assumes that all other variables, in particular interest rates, remain constant. If TL evaluates against other

currencies by 10%, the effect will be the reverse of the following amounts.

December 31, 2018 December 31, 2017

Equity(*) Profit or loss Equity(*) Profit or loss

US Dollar (26,616) (1,608,782) (4,863) (593,458)

Euro 315,745 310,452 (137,736) (177,817)

Total, net 289,129 (1,298,330) (142,599) (771,275)

(*) Equity effect includes the profit or loss effect of 10% devaluation of the TL against related currencies.

Interest rate risk

The principal risk to which non-trading portfolios are exposed is the risk of loss from fluctuations in the

future cash flows due to changes in market interest rates and to which trading portfolios are exposed is

the risk of loss from fluctuations in the fair values of financial instrument because of a change in market

interest rates. Interest rate risk is managed principally through monitoring interest rate gaps and by having

pre-approved limits for re-pricing bands. As at December 31, 2018 and 2017, interest rate profile of the

Group’s interest earning and interest-bearing financial instruments is:

Carrying amount

December 31,

2018

December 31,

2017

Financial assets with fixed interest rates

Available-for-sale fin. assets – government bonds issued by the Turkish

Government – FC (Note 8) 466,243,883 354,514,564

Cash at banks (Note 7) 107,982,804 96,175,304

Cash at banks with original maturity more than 3 months (Note 8) 7,817,028 68,646,801

Available-for-sale financial assets backing investment contracts – FC private

sector corporate bonds (Note 8) - 5,552,766

Held to maturity financial. assets – government bonds issued by the Turkish

Government – FC (Note 8) 40,480,281 35,090,709

Available-for-sale fin. assets – government bonds issued by the Turkish

Government – TL (Note 8) 9,200,745 10,348,998

Available-for-sale financial assets– FC private sector corporate bonds (Note 8) 50,540,306 18,641,041

Held to maturity fin. assets backing inv. Cont. – government bonds (Note 8) 11,935,341 4,549,037

Available-for-sale fin. assets backing inv. cont. – government bonds (Note 8) 1,155,707 3,895,823

Blocked cash at banks (Note 8) 142,715 12,931,963

Loans and receivables backing inv. cont. liab. – time deposit (Note 8) 3,331,276 4,930,659

Loans to the policyholders (Note 10) 678,259 533,382

Available-for-sale fin. assets – TL private sector cor. bonds (Note 8) 9,936,997 -

Financial assets with variable interest rates

Available-for-sale financial assets – debt securities indexed to consumer price

index (Note 8) 13,157,831 10,948,153

Held to maturity financial assets – government bonds (Note 8) 4,632,247 3,689,494

Available-for-sale financial assets backing investment contracts – government

bonds (Note 8) 3,027,612 2,523,836

Available-for-sale fin. assets – government bonds issued by the Turkish

Government (Note 8) - 1,988,024

Available-for-sale fin. assets – TL private sector cor. bonds (Note 8) 1,128,355 -

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

34

6 Management of financial risk (continued)

Market risk (continued)

Fair value sensitivity analysis for financial instruments

The Group classified both financial assets owned by the Group and financial assets backing investment

contract liabilities as financial assets at fair value through profit or loss, available-for-sale financial assets,

loans and receivables and held-to-maturity investment securities. Financial assets at fair value through

profit or loss and available-for-sale financial assets both owned by the Group and backing investment

contract liabilities are subject to market risk due to change in market interest rates. Profit or loss and

equity effects (without tax effects) of 100 bp changes in interest rates are shown below. This analysis

assumes that all other variables, in particular foreign currency rates remain constant. This analysis is

performed on the same basis as at and for the year ended December 31, 2017.

December 31, 2018

Profit or loss Equity(*)

100 bp

increase

100 bp

decrease

100 bp

increase

100 bp

decrease

Available-for-sale financial assets 11,955 11,955 (1,687,697) 1,783,374

Available-for-sale financial assets backing investment

contract liabilities - - (307,809) 314,835

Total 11,955 11,955 (1,995,506) 2,098,209

December 31, 2017

Profit or loss Equity(*)

100 bp

increase

100 bp

decrease

100 bp

increase

100 bp

decrease

Available-for-sale financial assets 18,953 18,953 (8,141,839) 8,455,322

Available-for-sale financial assets backing investment

contract liabilities - - (122,269) 125,424

Total 18,953 18,953 (8,264,108) 8,580,746

(*) Equity effect also includes profit or loss effect of the changes in interest rates.

The fair values of financial assets and liabilities

The Group has reclassified its quoted marketable securities as either financial assets at fair value through

profit or loss or as available-for-sale financial assets in the accompanying consolidated financial

statements and measured based on quoted market prices at the reporting date. The Group has also

measured its investment contract liabilities based on the market prices of those underlying securities

classified as financial assets at fair value through profit or loss or available-for-sale financial assets.

As at December 31, 2018, fair value of held to maturity investment securities with a carrying value of TL

57,047,867 (December 31, 2017: TL 43,329,240) was amounted to TL 56,045,401 (December 31, 2017:

TL 43,997,732). Held to maturity investment securities have quoted market prices that are in the Level 1

of fair value classification.

The Group management believes that carrying values of other financial assets and financial liabilities are

reasonable approximation of their fair values, considering their average maturities.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

35

6 Management of financial risk (continued)

Market risk (continued)

Classification of fair value measurement

IFRS 7 – Financial Instruments requires the classification of fair value measurements into a fair value

hierarchy by reference to the observability and significance of the inputs used in measuring fair value of

financial instruments measured at fair value to be disclosed. This classification basically relies on whether

the relevant inputs are observable or not. Observable inputs refer to the use of market data obtained from

independent sources, whereas unobservable inputs refer to the use of predictions and assumptions about

the market made by the Group. This distinction brings about a fair value measurement classification

generally as follows:

Level 1: Fair value measurements using quoted prices (unadjusted) in active markets for identical assets

or liabilities;

Level 2: Fair value measurements using inputs other than quoted prices included within Level 1 that are

observable for the asset or liability, either directly (as prices) or indirectly (derived from prices).

Level 3: Fair value measurements using inputs for the assets or liability that are not based on observable

market data (unobservable inputs)

Classification requires using observable market data if possible.

December 31, 2018

Level 1 Level 2 Level 3 Total

Financial assets:

Available-for-sale financial assets (Note 8) 550,208,119 1,509,879 - 551,717,998

Financial assets at fair value through profit or loss (Note 8) - - 12,900,044 12,900,044

Available-for-sale fin. assets backing inv. cont. liabilities (Note 8) 4,183,321 - - 4,183,321

Total financial assets measured at fair value 554,391,440 1,509,879 12,900,044 568,801,363

Financial liabilities:

Investment contract liabilities 9,961,072 - - 9,961,072

Total financial liabilities measured at fair value 9,961,072 - - 9,961,072

December 31, 2017

Level 1 Level 2 Level 3 Total

Financial assets:

Available-for-sale financial assets (Note 8) 396,440,780 2,508,416 - 398,949,196

Financial assets at fair value through profit or loss (Note 8) - - 1,395,474 1,395,474

Available-for-sale fin. assets backing inv. cont. liabilities (Note 8) 11,992,425 - - 11,992,425

Total financial assets measured at fair value 408,433,205 2,508,416 1,395,474 412,337,095

Financial liabilities:

Investment contract liabilities 10,736,151 - - 10,736,151

Total financial liabilities measured at fair value 10,736,151 - - 10,736,151

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

36

6 Management of financial risk (continued)

Capital management

The Group’s capital management policies include the following:

to comply with the insurance capital requirements required by the Turkish Treasury;

to safeguard the Group’s ability to continue as a going concern so that it can continue to provide

returns for shareholders and benefits for other stakeholders; and

to provide an adequate return to shareholders by pricing insurance contracts commensurately with

the level of risk.

In accordance with the “Circular regarding the measurement and assessment of capital adequacy of

insurance, reinsurance and individual pension companies” issued by the Turkish Treasury on 19 January

2008 dated and 26761 numbered Official Gazette, capital requirement is measured on a semi-annually

and standalone basis based on the statutory financial statements of insurance companies.

The Group has measured the minimum level of required capital and available capital as TL 267,290,312

TL and 316,861,189 respectively, as at June 30, 2018 (The Group has measured the minimum level of

required capital and available capital as TL 207,677,079 TL and 295,363,764 TL respectively, as at

December 31, 2017).

7 Cash and cash equivalents

As at December 31, 2018 and 2017, cash and cash equivalents are as follows:

December 31, 2018 December 31, 2017

Cash on hand 2,221 4,736

Cash at banks 108,147,723 97,343,135

Credit card receivables 17,402,245 12,642,577

Cash and cash equivalents 125,552,189 109,990,448

Interest income accruals on cash at banks (147,228) (5,210,100)

Cash and cash equivalents in the consolidated statement of

cash flows 125,404,961 104,780,348

As at December 31, 2018 and 2017, cash at banks are further analysed as follows:

December 31, 2018 December 31, 2017

Foreign currency denominated bank deposits

- time deposits 69,170,955 30,341,528

- demand deposits 721 4

69,171,676 30,341,532

Bank deposits in Turkish Lira

- demand deposits 164,198 1,167,827

- time deposits 38,811,849 65,833,776

38,976,047 67,001,603

Total 108,147,723 97,343,135

As at December 31, 2018 and 2017, interest rate interval for time deposits is as follows:

Interest rate per annum (%)

December 31, 2018 December 31, 2017

TL 7.50-29.50 7.50-15.85

US Dollars 0.60-4.50 2.75-3.70

Euro 0.30-2.25 1.75-2.25

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

37

8 Investment securities

As at December 31, 2018 and 2017 the investment portfolio of the Company is as follows:

December 31, 2018 December 31, 2017

Financial assets at fair value through profit or loss 12,900,044 1,395,474

Investment securities 624,240,202 540,780,284

Total investment securities 637,140,246 542,175,758

December 31, 2018 December 31, 2017

Group’s own portfolio:

Financial assets at fair value through profit or loss 12,900,044 1,395,474

Available for sale financial assets 551,717,998 398,949,196

Held to maturity investments 45,112,527 38,780,203

Time deposits with original maturity more than 3 months 7,959,742 81,578,764

Total Group’s own portfolio 617,690,311 520,703,637

Financial assets backing investment contract liabilities:

Financial assets at fair value through profit or loss - -

Available for sale financial assets 4,183,321 11,992,425

Held to maturity investments 11,935,340 4,549,037

Time deposits with original maturity more than 3 months 3,331,274 4,930,659

Total financial assets backing investment contract liabilities 19,449,935 21,472,121

Total investment securities 637,140,246 542,175,758

As at December 31, 2018 and 2017, the Group’s own portfolio is as follows:

December 31, 2018

Nominal

value Cost

Fair

value

Carrying

Value

Derivative financial instruments:

Derivatives - - 12,900,044 12,900,044

Financial assets at fair value through profit or loss - - 12,900,044 12,900,044

Fixed income securities:

Eurobonds issued by the Turkish Government – FC 453,489,580 483,877,708 466,243,883 466,243,883

Private sector corporate bonds – FC 55,666,850 51,162,113 50,540,306 50,540,306

Government bonds – TL 16,798,856 15,863,564 22,358,578 22,358,578

Private sector corporate bonds – TL 11,400,000 10,857,052 11,065,352 11,065,352

537,355,286 561,760,437 550,208,119 550,208,119 Non-fixed income securities:

Investment funds – FC 1,508,879 1,508,879 1,508,879

1,508,879 1,508,879 1,508,879

Available-for-sale financial assets 563,270,316 551,717,998 551,717,998

Fixed income securities:

Eurobonds issued by the Turkish Government – FC 38,930,660 42,198,246 40,003,514 40,480,281

Government bonds – TL 2,011,000 1,972,823 4,574,402 4,632,246

Held to maturity investment securities 44,171,069 44,577,916 45,112,527

Blocked cash at banks 141,696 142,715 142,715

Cash at banks with original maturity more than 3 months – TL 7,700,361 7,817,027 7,817,027

Loans and receivables 7,842,057

7,959,742 7,959,742

Total Group’s own portfolio 615,283,442 617,155,699 617,690,311

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

38

8 Investment securities (continued)

December 31, 2017

Nominal

value Cost

Fair

value

Carrying

Value

Derivative financial instruments:

Derivatives - - 1,395,474 1,395,474

Financial assets at fair value through profit or loss - - 1,395,474 1,395,474

Fixed income securities:

Eurobonds issued by the Turkish Government – FC 345,479,090 381,607,272 354,514,564 354,514,564

Private sector corporate bonds – FC 18,105,120 18,585,894 18,641,041 18,641,041

Government bonds – TL 18,748,311 20,625,307 23,285,175 23,285,175

420,818,473 396,440,780 396,440,780

Non-fixed income securities:

Investment funds – FC 2,508,416 2,508,416 2,508,416

2,508,416 2,508,416 2,508,416

Available-for-sale financial assets 423,326,889 398,949,196 398,949,196

Fixed income securities:

Eurobonds issued by the Turkish Government – FC 33,004,125 35,789,750 35,836,806 35,090,709

Government bonds – TL 2,011,000 1,972,823 3,813,248 3,689,494

Held to maturity investment securities 37,762,573 39,650,054 38,780,203

Blocked cash at banks 12,800,852 12,931,963 12,931,963

Cash at banks with original maturity more than 3 months – TL 66,939,055 68,646,801 68,646,801

Loans and receivables 79,739,907 81,578,764 81,578,764

Total Group’s own portfolio 540,829,369 521,573,488 520,703,637

As at December 31, 2018, the Group has TL 142,715 (December 31, 2017: TL 12,931,963) blocked deposits in favour of the Turkish Treasury (Note 8, 31) and has TL 74,735,977 (December 31, 2017: TL 73,230,683) blocked foreign currency government bonds under investment securities in the accompanying consolidated financial statements.

As at December 31, 2018 and 2017, financial assets backing investment contract liabilities are as follows:

December 31, 2018

Nominal value Cost

Fair value

Carrying value

Fixed income securities:

Government bonds – TL 2,531,000 3,583,079 4,183,321 4,183,321

Available-for-sale financial assets 3,583,079 4,183,321 4,183,321 Fixed income securities:

Eurobonds issued by the Turkish Government – FC 7,102,215 7,719,910 7,297,938 7,391,586

Government bonds – TL 4,329,343 4,375,442 4,169,547 4,543,754

Held to maturity investment securities 12,095,352 11,467,485 11,935,340

Cash at banks – TL 361,680 362,064 362,064

Cash at banks – FC 2,906,381 2,969,210 2,969,210

Loans and receivables 3,268,061 3,331,274 3,331,274

Total financial assets backing investment contract liabilities 18,946,492 18,982,080 19,449,935

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

39

8 Investment securities (continued)

December 31, 2017

Nominal value Cost

Fair value

Carrying value

Fixed income securities:

Government bonds – TL 5,181,000 6,117,798 6,419,659 6,419,659

Private sector corporate bonds – FC 5,469,255 5,655,529 5,572,766 5,572,766

Available-for-sale financial assets 11,773,327 11,992,425 11,992,425 Fixed income securities:

Government bonds – TL 4,329,343 4,375,442 4,347,678 4,549,037

Held to maturity investment securities 4,375,442 4,347,678 4,549,037

Cash at banks – TL 3,852,355 3,922,818 3,922,818

Cash at banks – FC 1,004,442 1,007,841 1,007,841

Loans and receivables 4,856,797 4,930,659 4,930,659

Total financial assets backing investment contract liabilities 21,005,566 21,270,762 21,472,121

As at December 31, 2018 and 2017, foreign currency denominated securities are as follows:

Amount in original currency TL equivalent

December 31, 2018 December 31, 2017

December 31,

2018 December 31, 2017

US Dollar 107,134,362 109,614,930 563,623,166 413,456,555

Euro 11,956,953 8,861,724 72,076,505 40,015,114

Total 635,699,671 453,471,669

As at December 31, 2018 and 2017, interest rates for the investment securities are as follows:

December 31, 2018 December 31, 2017

Financial assets at fair value through profit and loss:

Eurobonds issued by the Turkish Government backing inv. contract liabilities -

Available for sale financial assets:

Government bonds and treasury bills owned by the Group 6.94%-27.27% 6.94%- 13.05%

Government bonds and treasury bills backing inv. contract liabilities 9.02%-9.06% 9.02%- 10.44%

FC Private sector corporate bonds owned by the Group 2.73%-11.68% 4.50%- 7.71%

Private sector eurobonds backing investment contract liabilities - 4.19%- 4.67%

Eurobonds issued by the Turkish Government owned by the Group 3.60%-6.41% 2.43%- 4.74%

Held to maturity investment securities:

Government bonds and treasury bills owned by the Group 4.39%-4.66% 4.22%- 4.42%

Government bonds and treasury bills backing inv. contract liabilities 4.43% 10.32%- 10.65%

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

40

8 Investment securities (continued)

As at December 31, 2018 and 2017, the movement of securities, excluding derivative financial instruments

and loans and receivables is follows:

December 31, 2018

Group’s own portfolio Financial assets backing inv. contract liabilities

Fin. assets at

fair value

through

profit or loss

Available-for-

sale financial

assets

Held to

maturity

investment

securities

Fin. assets at fair

value through

profit or loss

Available for

sale financial

assets

Held to

maturity

investment

securities Total

Balance at the beg. of the year - 398,949,196 38,780,203 - 11,992,425 4,549,037 454,270,861

Foreign currency differences of

financial assets - 77,412,621 11,457,191 - - - 88,869,812

Acquisitions during the year - 259,158,663 - - - - 259,158,663

Transfers - - (5,420,794) - - 5,420,794 -

Disposals (either sold or settled) - (84,849,475) - - (8,263,508) - (93,112,983)

Impairment of financial assets - (1,988,762) - - - - (1,988,762)

Change in the fair value of financial

assets - (9,290,340) - - (125,827) - (9,416,167)

Change in amortised costs of the

financial assets - (87,673,905) 295,927 - 580,231 1,965,509 (84,832,238)

Balance at the end of the year - 551,717,998 45,112,527 - 4,183,321 11,935,340 612,949,186

December 31, 2017

Group’s own portfolio Financial assets backing inv. contract liabilities

Fin. assets at

fair value

through

profit or loss

Available-for-

sale financial

assets

Held to

maturity

investment

securities

Fin. assets at fair

value through

profit or loss

Available for

sale financial

assets

Held to

maturity

investment

securities Total

Balance at the beg. of the year - 315,671,971 36,834,697 109,150 14,902,355 4,553,694 372,071,867

Foreign currency differences of

financial assets - 18,431,077 2,233,696 - 349,639 - 21,014,412

Acquisitions during the year - 263,106,119 - - - - 263,106,119

Transfers - - - - - - -

Disposals (either sold or settled) - (169,894,330) - (109,150) (3,571,207) - (173,574,687)

Impairment of financial assets - (1,738,236) - - - - (1,738,236)

Change in the fair value of financial

assets - 6,672,615 - - 15,157 - 6,687,772

Change in amortised costs of the

financial assets - (33,300,020) (288,190) - 296,481 (4,657) (33,296,386)

Balance at the end of the year - 398,949,196 38,780,203 - 11,992,425 4,549,037 454,270,861

Total securities blocked in favour of the Turkish Treasury are as follows:

December 31, 2018

Nominal

value Cost Fair value

Carrying

value

Financial assets backing investment contract liabilities – debt

securities 6,860,343 7,958,521 8,352,866 8,727,074

Financial assets backing investment contract liabilities –

bank deposits - 3,268,061 3,331,276 3,331,276

Total (Note 30) 11,226,582 11,684,142 12,058,350

December 31, 2017

Nominal

value Cost Fair value

Carrying

value

Financial assets backing investment contract liabilities –

debt securities 14,979,598 16,148,769 16,340,103 16,541,462

Financial assets backing investment contract liabilities –

bank deposits - 4,856,797 4,930,659 4,930,659

Total (Note 30) 21,005,566 21,270,762 21,472,121

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

41

9 Financial liabilities

As at December 31, 2018 and 2017, financial liabilities are as follows:

December 31, 2018 December 31, 2017

Other financial liabilities 170,807 304,066

Total financial liabilities 170,807 304,066

Obligations under repurchase agreements

The Group raises funds by selling financial instruments under agreements to repay the funds by

repurchasing the instruments at future dates at the same price plus interest at a predetermined rate.

Repurchase agreements are commonly used as a tool for short-term financing of interest-bearing assets,

depending on the prevailing interest rates.

Derivative financial instruments held for trading purposes

A derivative financial instrument is a financial contract between two parties where payments are

dependent upon movements in price in one or more underlying, such as financial instrument prices,

reference rates, commodity prices or indices. The fair value of derivative financial instruments is

calculated by using forward exchange rates at the reporting date.

As at December 31, 2018 and 2017, notional amounts of derivative financial instruments held for trading

purposes are as follows:

December 31, 2018

Maturity: Up to 1 month 1 - 3 months 3-12 months Total

Currency swaps:

Purchase-TL 224,905,742 245,979,762 77,917,377 548,802,881

Sales-US Dollars 218,687,748 240,114,410 82,053,321 540,855,479

Purchase-TL 57,218,409 15,296,929 5,946,766 78,462,104

Sales-EUR 55,139,247 14,945,455 5,937,580 76,022,282

Forwards:

Purchase-TL - 18,945,268 - 18,945,268

Sales-US Dollars - 18,939,240 - 18,939,240

Purchase-TL 85,557 11,444 - 97,001

Sales-EUR 81,807 11,181 - 92,988

December 31, 2017

Maturity: Up to 1 month 1 - 3 months 3-12 months Total

Currency swaps:

Purchase-TL 31,453,062 157,908,472 213,940,708 403,302,242

Sales-US Dollars 31,686,228 159,973,843 210,430,232 402,090,303

Purchase-TL 22,444,995 10,117,345 5,167,595 37,729,935

Sales-EUR 23,511,501 10,837,200 4,987,652 39,336,353

Forwards:

Purchase-TL - 4,523,295 - 4,523,295

Sales-US Dollars - 4,526,280 - 4,526,280

Purchase-TL - 4,516,434 - 4,516,434

Sales-EUR - 4,515,500 - 4,515,500

As at December 31, 2018, derivative financial instruments held for trading purposes in a net asset position

amount to TL 12,900,044 (December 31, 2017: TL 1,395,474) (Note 8).

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

42

10 Premium and other insurance receivables

December 31, 2018 December 31, 2017

Policyholders and intermediaries 148,643,005 112,442,088

Loans to the policyholders 678,259 533,382

Provision for overdue receivables (Note 6) (7,368,065) (8,261,591)

Total premium and other insurance receivables 141,953,199 104,713,879

The Group individually assesses all premium receivables matured for more than 60 days and books a

provision for the whole outstanding amount for any potential impairment. Accordingly, as at 31 December

2018, the provision for overdue receivables amounting to TL 7,368,065 (December 31, 2017: TL

8,261,591) including the doubtful receivables for which the Group has started legal procedures, is

provided in relation to premium and other insurance receivables.

11 Amounts due from/to insurance and reinsurance companies

As at December 31, 2018 and 2017, amounts due from and due to reinsurance companies comprised the

followings:

Due from insurance and reinsurance companies December 31, 2018 December 31, 2017

Aksigorta AŞ 72,945,794 46,446,841

Zurich Sigorta AŞ 1,499,151 1,797,905

SBN Sigorta AŞ 196,951 1,060,717

Others 174,803 164,148

CCR Re 125,140 -

Milli Reasürans TAŞ 11,602 -

Munich Re - -

Discount of due from insurance and reinsurance companies (1,821,983) (1,474,309)

Provision for overdue receivables (Note 6) (151,445) (151,446)

Total 72,980,013 47,843,856

Due to insurance and reinsurance companies December 31, 2018 December 31, 2017

Global Benefits Group 1,232,565 2,430,821

Scor Re 574,190 1,860,669

Others 1,782,630 61,022

Total 3,589,385 4,352,512

12 Payables to medical networks and other insurance payables

As at December 31, 2018 and 2017, other insurance payables comprised following:

December 31, 2018 December 31, 2017

Payables to brokerage companies 4,191,445 3,180,005

Payables to agencies 2,786,777 2,155,945

Payables to policyholders 990,912 2,126,789

Others 3,549 85,474

Total 7,972,683 7,548,213

As at December 31, 2018, the Group has TL 136,993,707 (December 31, 2017: TL 128,006,424) payable

to medical networks and pharmacies.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

43

13 Other assets

As at December 31, 2018 and 2017, other assets comprised following:

December 31, 2018 December 31, 2017

Income accruals (*) 20,497,437 12,239,155

Prepaid expenses 10,863,873 3,371,185

Prepaid taxes 8,659,876 -

Advances given 754,614 244,874

Miscellaneous receivables 285,809 514,066

Deposits given 53,642 48,192

Other assets 479 1,876

Receivables from related parties (Note 31) - 46,676

Total 41,115,730 16,464,024

(*) Income accruals mainly include accruals for loss sharing agreements signed with corporate customers based on the performance

of their health insurance contracts.

14 Investment properties, net

The Group has no investment property as at December 31, 2018 and 2017.

15 Property and equipment, net

For the years ended December 31, 2018 and 2017, the movement of property and equipment is as follows:

January 1,

2018 Additions Disposals

December 31,

2018

Cost:

Building 1,026,779 - - 1,026,779

Leasehold improvements 1,961,900 92,776 - 2,054,676

Furniture and fixtures 6,903,087 1,337,457 (328,605) 7,911,939

Motor Vehicles - 337,800 - 337,800

9,891,766 1,768,033 (328,065) 11,331,194

Accumulated depreciation:

Building (368,177) (54,722) - (422,949)

Leasehold improvements (1,527,688) (203,989) - (1,731,677)

Furniture and fixtures (4,100,084) (1,227,830) 233,812 (5,094,102)

Motor Vehicles - (19,207) - (19,207)

(5,995,949) (1,505,798) 233,812 (7,267,935)

Net carrying value 3,895,817 4,063,260

January 1,

2017 Additions Disposals

December 31,

2017

Cost:

Building 1,026,779 - - 1,026,779

Leasehold improvements 1,938,055 23,845 - 1,961,900

Furniture and fixtures 6,387,973 552,269 (37,155) 6,903,087

9,352,807 576,114 (37,155) 9,891,766

Accumulated depreciation:

Building (340,791) (27,386) - (368,177)

Leasehold improvements (1,221,664) (306,024) - (1,527,688)

Furniture and fixtures (2,896,087) (1,221,841) 17,844 (4,100,084)

(4,458,542) (1,555,251) 17,844 (5,995,949)

Net carrying value 4,894,265 3,895,817

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

44

16 Intangible assets, net

For the years ended December 31, 2018 and 2017, the movement of intangible assets is as follows:

January 1,

2018 Additions Disposals

December 31,

2018

Cost:

Rights 132,404 107,380 - 239,784

Computer software 6,699,023 447,880 - 7,146,903

6,831,427 555,260 - 7,386,687

Accumulated amortisation:

Rights (17,113) (11,290) - (28,404)

Computer software (3,133,029) (891,618) - (4,024,647)

(3,150,142) (902,909) - (4,053,051)

Net carrying value 3,681,285 3,333,636

January 1,

2017 Additions Disposals

December 31,

2017

Cost:

Rights 52,936 79,468 - 132,404

Computer software 4,681,034 2,017,989 - 6,699,023

4,733,970 2,097,457 - 6,831,427

Accumulated amortisation:

Rights (11,327) (5,786) - (17,113)

Computer software (2,759,660) (373,369) - (3,133,029)

(2,770,987) (379,155) - (3,150,142)

Net carrying value 1,962,983 3,681,285

17 Income taxes

As at December 31, 2018 and 2017, prepaid income taxes are netted off with the current income tax

payable as stated below:

December 31, 2018 December 31, 2017

Income taxes payable 30,279,174 16,576,912

Prepaid income taxes (30,279,174) (13,708,570)

Income taxes payable / (Current tax assets) - 2,868,342

As at December 31, 2018 and 2017, deferred tax asset/ (liability) is attributable to the items detailed in

the table below:

December 31, 2018 December 31, 2017

Technical provisions 6,371,903 2,903,892

Profit/loss share provisions 2,624,436 2,074,682

Difference in valuation of financial assets (2,445,249) (1,626,007)

Employee related provisions 5,810,584 3,133,307

Provision for overdue premium receivables 470,643 597,387

Tax losses carried forward 79,536 404,665

Provision for legal cases 110,664 173,645

Income accrual (3,037,014) (1,300,397)

Others (78,050) (149,690)

Deferred tax assets, net 9,907,453 6,211,484

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

45

17 Income taxes (continued)

Income tax expense for the years ended December 31, 2018 and 2017 are as follows:

December 31, 2018 December 31, 2017

Income tax expense recognised in profit or loss:

- Current tax charge (30,213,863) (16,280,097)

- Deferred tax benefit/(charge) 1,930,312 371,454

Income tax expense (28,283,550) (15,908,643)

As at and for the year ended December 31, 2018 and 2017, movement of deferred tax balances are as

follows:

December 31, 2018 December 31, 2017

Deferred tax assets balance at previous year 6,211,484 6,911,935

Deferred tax recognised in profit or loss 1,930,312 371,454

Deferred tax recognised in other comprehensive income 1,765,657 (1,071,905)

Deferred tax assets balance at current year 9,907,453 6,211,484

The total provision for taxes on income is different than the amount computed by applying the statutory

tax rate to income before provision for taxes as shown in the following reconciliation:

December 31, 2018 % December 31,2017 %

Profit before taxes 131,705,964 79,660,253

Taxes on income per statutory tax rate (28,975,312) 22.00 (15,932,051) 20.00

Change in tax rates 720,939 (0,55) - -

Non-deductible expenses and tax exempt

income, net (29,177) 0.02 23,408 (0.03)

Income tax expense (28,283,550) 21.47 (15,908,643) 19.97

18 Deferred acquisition costs

As at December 31, 2018 and 2017, deferred acquisition costs are as follows:

December 31, 2018 December 31, 2017

Deferred commission expenses 29,489,931 24,358,333

Deferred other acquisition costs 9,375,824 6,750,651

Deferred acquisition costs 38,865,755 31,108,984

Acquisition costs are those costs that vary with and are primarily related to the acquisition of new

and7renewal insurance contracts. Commissions and other costs (for example, salaries of certain

employees involved in direct sales functions) that are primarily related to insurance contracts issued or

renewed during the period in which the costs are incurred are considered as acquisition costs and deferred

over the life of the insurance contracts.

As at December 31, 2018 and 2017, movements of deferred commission expenses, are as follows:

December 31, 2018 December 31, 2017

Deferred commission expenses at the beginning of the year 24,358,333 22,811,945

Expenses deferred during the year 78,566,857 68,050,247

Amortisation (73,435,259) (66,503,859)

Deferred commission expenses at the end of the year 29,489,931 24,358,333

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

46

18 Deferred acquisition costs (continued)

As at December 31, 2018 and 2017, movements of deferred other acquisition costs, are as follows:

December 31, 2018 December 31, 2017

Deferred other acquisition costs at the beginning of the year 6,750,651 4,899,379

Expenses deferred during the year 23,552,639 16,892,285

Amortisation (20,927,466) (15,041,013)

Deferred other acquisition costs at the end of the year 9,375,824 6,750,651

19 Employee benefits

As at December 31, 2018 and 2017, employee benefits are as follows:

December 31, 2018 December 31, 2017

Bonus provision 13,858,036 8,277,000

Long term incentive plan 7,048,733 3,955,000

Reserve for employee severance indemnity 3,508,694 1,935,725

Reserve for vacation pay liability 2,353,979 1,493,460

Total employee benefits 26,769,441 15,661,185

For the years ended December 31, 2018 and 2017, movement of reserve for employee severance

indemnity is as follows:

December 31, 2018 December 31, 2017

Balance at the beginning of the year 1,935,725 759,206

Service costs 671,100 1,449,506

Interest costs 1,511,240 217,499

Paid during the year (609,371) (498,864)

Actuarial differences (*) - 8,378

Balance at the end of the year 3,508,694 1,935,725

(*) As at December 31, 2018 and 2017, service and interest costs on reserve for employee severance indemnity has

been recorded in profit or loss, whereas actuarial differences have been accounted for in the consolidated other

comprehensive income.

20 Other provisions

As at December 31, 2018 and 2017, other provisions are as follows:

December 31, 2018 December 31, 2017

Profit share provisions for health insurance agreements 17,389,153 13,543,570

Provision for personnel related expenses - 1,218,498

Provision for legal cases 503,019 868,226

Commission provisions to intermediaries for outstanding sales

campaigns 16,530 580,110

Provision for portfolio management success fees 480,000 240,000

Others 335,453 288,362

Total other provisions 18,724,155 16,738,766

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

47

21 Other liabilities

As at December 31, 2018 and 2017, other liabilities are as follows:

December 31, 2018 December 31, 2017

Deposits and advances received (*) 8,647,687 38,549,695

Payable to suppliers 2,126,319 3,603,242

Taxes payable other than on income 2,902,479 3,352,044

Payable to personnel 2,453,789 2,010,134

Other expense accruals 1,029,173 430,110

Deferred commission income 441,307 -

Payable to related parties (Note 31) 523,013 282,755

Total other liabilities 18,123,768 48,227,980

(*) The balance includes prepayments of some corporate clients’ health insurance policies that have not started as at

December 31,2018 and 2017.

22 Insurance contract liabilities

Insurance contract liabilities and reinsurance assets as at December 31, 2018 and 2017 are as follows:

December 31, 2018 December 31, 2017

Reserve for unearned premiums 379,180,647 288,990,508

Claims provision 85,812,860 47,163,754

Life mathematical reserves 2,813,907 4,609,962

Insurance contract liabilities 467,807,414 340,764,224

Reserve for unearned premiums, ceded 3,574,362 2,522,054

Claims provision, ceded 8,080,711 7,404,983

Reinsurance assets 11,655,073 9,927,037

Movements in insurance liabilities and reinsurance assets

Claims

December 31, 2018 Gross Ceded Net

Total at the beginning of the year 47,163,754 (7,404,983) 39,758,771

Cash paid for claims settled during year (860,102,333) 21,071,306 (839,031,027)

Claims incurred in current year and change in the estimates of

claims amount incurred in previous years 898,751,439 (21,747,034) 877,004,405

Total at the end of the year 85,812,860 (8,080,711) 77,732,149

December 31, 2018

Notified claims 79,516,500 (7,957,804) 71,558,696

Incurred but not reported 6,296,360 (122,907) 6,173,453

Total at the end of the year 85,812,860 (8,080,711) 77,732,149

December 31, 2017 Gross Ceded Net

Total at the beginning of the year 27,207,566 (5,020,628) 22,186,938 Cash paid for claims settled during year (698,300,050) 16,684,378 (681,615,672) Claims incurred in current year and change in the estimates of

claims amount incurred in previous years 718,256,238 (19,068,733) 699,187,505

Total at the end of the year 47,163,754 (7,404,983) 39,758,771

December 31, 2017 Gross Ceded Net

Notified claims 42,038,133 (7,141,646) 34,896,487 Incurred but not reported 5,125,621 (263,337) 4,862,284

Total at the end of the year 47,163,754 (7,404,983) 39,758,771

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

48

22 Insurance contract liabilities (continued)

Reserve for unearned premiums and short term insurance risk

December 31, 2018 Gross Ceded Net

Reserve for unearned premiums at the beginning of

the year 288,990,508 (2,522,054) 286,468,454

Premiums written during the year 1,143,221,713 (21,089,251) 1,122,132,462

Premiums earned during the year (1,053,031,574) 20,036,943 (1,032,994,631)

Reserve for unearned premiums 379,180,647 (3,574,362) 375,606,285

December 31, 2017 Gross Ceded Net

Reserve for unearned premiums at the beginning of

the year 232,668,801 (1,503,016) 231,165,785

Premiums written during the year 912,591,567 (17,826,650) 894,764,917

Premiums earned during the year (856,269,860) 16,807,612 (839,462,248)

Reserve for unearned premiums 288,990,508 (2,522,054) 286,468,454

Reserve for long term risk contracts:

December 31, 2018 December 31, 2017

Mathematical reserve for long term life contracts 2,813,907 4,609,962

Mathematical reserve for long term risk contracts 2,813,907 4,609,962

Claim development tables

The general insurance claims provision is sensitive to the some key assumptions. The sensitivity of certain

assumptions like legislative change, uncertainty in the estimation process, etc, is not possible to quantify.

Furthermore, because of delays that arise between occurrence of a claim and its subsequent notification

and eventual settlement, the outstanding claim provisions are not known with certainty at the reporting

date.

Consequently, the ultimate liabilities will vary as a result of subsequent developments. Differences

resulting from reassessment of the ultimate liabilities are recognised in subsequent consolidated financial

statements.

The table below indicates the impact of various changes in assumptions which are within a reasonable

range of possible outcomes given the uncertainties involved in the estimation process.

The table demonstrates the effect of change in key assumptions whilst other assumptions remain

unchanged, if these assumptions were changed in a single calendar year. The correlation of assumptions

will have a significant effect in determining the ultimate claims liabilities, but to demonstrate the impact

on the claims liabilities due to changes in assumptions, these assumptions changes had to be done on an

individual basis. It should also be stressed that these assumptions are non-linear and larger or smaller

impacts cannot easily be gleaned from these results.

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

49

22 Insurance contract liabilities (continued)

Claim development tables (continued)

December 31, 2018

Accident year 2013 2014 2015 2016 2017 2018 Total

Accident year 230,920,742 340,230,546 443,791,798 628,130,225 764,289,770 961,098,750 3,372,461,832

1 year later 235,520,030 338,824,721 443,319,642 626,526,073 759,390,715 2,403,581,180

2 years later 233,480,410 338,878,019 442,885,715 623,953,813 1,639,197,957

3 years later 233,802,394 338,583,090 439,980,600 1,012,366,084

4 years later 233,839,498 336,756,545 570,596,043

5 years later 234,075,395 234,075,395

Current estimate of cum. claims 234,075,395 336,756,545 439,980,600 623,953,813 759,390,715 961,098,750 3,355,255,818

Cumulative payments to date (260,767,998) (362,842,666) (484,929,609) (658,707,069) (787,556,833) (667,280,669) (3,222,084,843)

Liability recognised (42,763) 89,917 776,321 4,677,998 20,605,032 55,296,611 81,403,116

Liability recognised for the years before 2012 6,713,607

Claims provision for life branch 4,111,913

Discounting of claims provision 3,683,752

Total claims provision, gross as per the consolidated statement of financial position 88,544,883

December 31, 2018

Accident year 2013 2014 2015 2016 2017 2018 Total

Accident year 230,896,813 333,241,480 442,761,374 615,227,081 724,608,230 905,802,139 3,252,537,117

1 year later 231,886,438 331,236,434 443,319,642 615,262,510 742,049,424 2,363,754,448

2 years later 230,997,205 332,785,736 434,923,602 601,542,213 1,600,248,757

3 years later 231,770,300 332,496,109 438,959,026 1,003,225,435

4 years later 231,807,083 329,838,843 561,645,926

5 years later 230,065,946 230,065,946

Current estimate of cum. claims 230,065,946 329,838,843 438,959,026 601,542,213 742,049,424 905,802,139 3,248,257,591

Cumulative payments to date (230,710,169) (329,882,773) (438,213,254) (598,547,873) (722,135,878) (854,588,406) (3,174,078,353)

Liability recognised (644,224) (43,930) 745,771 2,994,341 19,913,546 51,213,733 74,179,237

Liability recognised for the years before 2012 5,687,103

Claims provision for life branch 3,860,018

Discounting of claims provision 3,262,185

Total claims provision, net of ceded as per the consolidated statement of financial position 80,464,173

December 31, 2017

Accident year 2012 2013 2014 2015 2016 2017 Total

Accident year 178,512,973 234,920,742 340,230,546 443,791,798 628,130,225 764,289,770 2,589,876,054

1 year later 178,222,895 235,520,030 338,824,721 443,319,642 626,526,073 - 1,822,413,361

2 years later 177,548,057 233,480,410 338,878,019 442,885,715 - - 1,192,792,201

3 years later 176,576,274 233,802,394 338,583,090 - - - 748,961,758

4 years later 176,504,758 233,839,499 - - - - 410,344,257

5 years later 176,497,114 - - - - - 176,497,114

Current estimate of cum. claims 176,497,114 233,839,498 338,583,090 442,885,715 626,526,073 764,289,770 2,582,621,260

Cumulative payments to date (176,474,858) (233,068,053) (336,775,155) (442,038,276) (622,536,599) (724,608,230) (2,535,501,171)

Liability recognised 22,256 771,445 1,807,935 847,439 3,989,474 39,681,540 47,120,089

Liability recognised for the years before 2011 1,327,493

Claims provision for life branch 1,456,277

Discounting of claims provision (2,740,105)

Total claims provision, gross as per the consolidated statement of financial position 47,163,754

December 31, 2017

Accident year 2012 2013 2014 2015 2016 2017 Total

Accident year 157,237,904 230,896,813 333,241,480 442,761,374 605,568,614 746,836,606 2,516,542,791

1 year later 156,982,397 231,485,836 331,864,534 442,290,314 604,022,081 - 1,766,645,162 2 years later 156,387,986 229,481,152 331,916,737 441,857,395 - - 1,159,643,270 3 years later 155,532,020 229,797,621 331,627,867 - - - 716,957,508 4 years later 155,469,027 229,834,089 - - - - 385,303,116 5 years later 155,462,294 - - - - - 155,462,294

Current estimate of cum. claims 155,462,294 229,834,089 331,627,867 441,857,395 604,022,081 746,836,606 2,509,640,332

Cumulative payments to date (155,441,467) (229,605,625) (329,933,353) (441,061,140) (601,822,479) (711,293,753) (2,469,157,817)

Liability recognised 20,827 228,464 1,694,514 796,255 2,199,602 35,542,853 40,482,515

Liability recognised for the years before 2011 583,878

Claims provision for life branch 1,168,532

Discounting of claims provision (2,476,154)

Total claims provision, net of ceded as per the consolidated statement of financial position 39,758,771

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

50

23 Investment contract liabilities

As at December 31, 2018 and 2017 movement for investment contract liabilities is as follows:

December 31, 2018 December 31, 2017 Opening balance 19,848,896 16,786,818

Contributions during the year 591,308 714,386

Withdrawals during the year (12,029,861) (4,916,928)

Change in share of policyholder in unrecognised gain/(losses) of financial assets backing liabilities

(33,795)

33,795

Change in profit sharing 397,652 627,729

Foreign exchange differences 2,685,998 303,864

Ending balance 11,460,198 13,549,664

Profit sharing rates of investments contracts as at December 31, 2018 and 2017 are as follows:

TL Fund (For the policies with

distribution rate 90%)

TL Fund (For the policies with

distribution rate 95%) USD Fund Euro Fund

December 31, 2018 9.07% 9.58% 4.44% 2.02% December 31, 2017 9.55% 9.48% 3.90% 1.64%

24 Equity

The authorized nominal share capital of the Company as at December 31, 2018 amounts to TL 116,500,000 (December 31, 2017: TL 116,500,000) and is held as follows:

December 31, 2018 December 31, 2017

Share-holding % TL Share-holding % TL

Burau Ventures Sdn Bhd 100.00 116,500,000 100.00 116,500,000

Total paid capital 100.00 116,500,000 100.00 116,500,000

Inflation adjustment to share capital (*) 2,510,960 2,510,960

Share capital 119,010,960 119,010,960

(*) Inflation adjustment to share capital represents the restatement effect of cash contributions to share capital based on the provisions of IAS 29, ‘’Financial Reporting in Hyper-inflationary Economies’’.

At December 31, 2018, share capital of the Group as adjusted for the effects of inflation pursuant to IAS 29 at December 31, 2005, amounts to TL 119,010,960 (December 31, 2017: TL 119,010,960).

Mehmet Ali Aydınlar transferred its 10% ownership on the Company’s shares to Burau Ventures Sdn Bhd. in 2016.

Retained earnings as per the statutory financial statements, other than legal reserves, are available for distribution subject to the legal reserve requirement referred to below.

Fair value reserves of available-for-sale financial assets

Fair value reserve comprises the cumulative net change in the fair value of available-for-sale financial assets until the assets are derecognised or impaired.

Legal reserves

Under the Turkish Commercial Code, legal reserves are composed of primary and secondary reserves. Primary legal reserves are set aside as 5% of the legal term profit until it reaches up to 20% of the company capital. Secondary legal reserves are set aside as 10% of the divided distributions exceeding 5% of the company capital. Primary and secondary legal reserves cannot be distributed unless they exceed 50% of total capital. However, in the event that free reserves are completely consumed, those can be used to cover the losses. As at December 31, 2018, total amount of legal reserves amount to TL 9,126,051 (December 31, 2017: TL 5,945,070).

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

51

24 Equity (continued)

Legal reserves (continued)

In the Acıbadem Sigorta General Assembly meeting dated March 30, 2018 it has been decided that, of the total net profit of the year ended December 31, 2017 amounting to TL 63,198,227 TL 3,159,912 shall be set aside as 5% of the remaining balance as primary legal reserves and the remaining amount of TL 60,038,315 shall be classified as retained earnings. As at the reporting date, the profit distribution has been completed.

In the ASA General Assembly meeting dated March 26 ,2018 it has been decided that, of the total net profit of the year ended December 31, 2017 amounting to TL 421,371 TL 21,069 shall be set aside as 5% of the remaining balance as primary legal reserves and the remaining amount of TL 400,302 shall be classified as retained earnings. As at the reporting date, the profit distribution has been completed.

25 Fees and commission income

Fees and commission income for the years ended December 31, 2018 and 2017 are as follows:

December 31,

2018

December 31,

2017

Commission income due to intermediary operations 416,832 371,084

Fees and commission income 416,832 371,084

26 Operating expenses

Operating expenses for the years ended December 31, 2018 and 2017 are as follows:

December 31,

2018

December 31,

2017

Personnel expenses 71,827,597 56,063,886

Consultancy expenses 2,121,040 2,310,753

Rent expenses 2,589,457 2,246,615

Depreciation and amortisation expenses 2,415,269 1,934,406

Transportation expenses 2,161,480 1,801,792

Tax, duties and charges expenses 342,541 1,038,444

Legal expenses 404,487 335,849

Change in other deferred acquisition expenses (2,625,172) (1,851,272)

Others 7,771,570 7,922,380

Total 90,287,754 71,802,853

Personnel expenses for the years ended December 31, 2018 and 2017 are as follows:

December 31,

2018

December

31,2017

Salaries 31,384,362 29,292,963

Annual performance bonus 13,858,036 8,128,184

Social security premiums 7,069,512 5,624,048

Premiums and commissions to sales staff 6,778,474 4,926,942

Long term incentive plan 7,048,733 3,955,000

Provision for employee termination benefits 1,572,968 1,168,142

Provision for unused vacations 860,519 116,067

Other fringe benefits 3,254,993 2,852,540

Total 71,827,597 56,063,886

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

52

27 Investment income and finance costs

Investment income and finance costs for the years ended December 31, 2018 and 2017 are as follows:

December 31,

2018

December 31,

2017

Interest income from bank deposits 16,889,861 14,907,882

Interest income from investment securities 454,506 69,332,157

Impairment provision for financials assets (3,214,987) (1,738,236)

Foreign exchange gains/(losses), net 9,348,076 (769,260)

Other finance income/(expense) - (2,459,748)

Total investment income 134,400,219 79,272,795

December 31,

2018

December 31,

2017

Interest expense for repurchase transactions (1,199,628) (14,903)

Portfolio management fee (318,171) (225,046)

Total finance costs (1,517,799) (239,949)

28 Other income and expenses

Other income and expenses for the years ended December 31, 2018 and 2017 are as follows:

December 31,

2018

December 31,

2017

Other income 510,735 374,018

Total other income 510,735 374,018

December 31,

2018

December 31,

2017

Provision expenses for premium receivables 746,938 (568,012)

Provision expenses for lawsuits against the Group 365,207 (78,018)

Other provisions expenses/reversal income (47,479) (144,525)

Total other expenses 1,064,666 (790,555)

Provision expense for subrogation receivables amounting to TL 618,865 (2017: TL 824,251) are booked in

other technical income.

29 Other technical income and expenses

Other technical income for the years ended December 31, 2018 and 2017 are as follows:

December 31,

2018

December 31,

2017

Accrual for loss sharing contracts, net of ceded (1,555,841) 5,546,271

Profit sharing income from pools 2,003,006 9,352

Other technical income 5,404,519 60,372

Total 5,851,684 5,615,995

Other technical expenses for the years ended December 31, 2018 and 2017 are as follows:

December 31,

2018

December 31,

2017

Provision for profit sharing in health contracts (260,518) (4,142,352)

Other technical income 260,518 (141,614)

Total - (4,283,966)

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary

Notes to the Consolidated Financial Statements

As at and For the Year Ended December 31, 2018

(Currency: Turkish Lira (TL) unless otherwise indicated)

53

30 Blocked securities and bank deposits

In order to protect the interests of policyholders, under Insurance Law, insurance companies are obliged

to deposit investments within two months in a blocked account with a state bank in favour of Turkish

Treasury. Accordingly the following guarantees have been issued to the Turkish Treasury based on the

financial results:

December 31, 2018 December 31, 2017

Blocked bank deposits (Note 8) 3,473,990 17,862,622

Blocked securities (Note 8) 77,985,600 85,799,988

31 Related party balances and transactions

Parties are considered to be related if one party has the ability to control the other party or exercise

significant influence over the other party in making financial and operating decisions. For the purpose of

these consolidated financial statements, shareholders and Group companies are referred to as related

parties. Related parties also include individuals that are principal owners and management and members

of the Group’s Board of Directors and their families.

In the course of conducting its insurance business, the Group conducted some business transactions with

related parties on commercial terms.

As at December 31, 2018 and 2017, outstanding balances with related parties are as follows:

December 31, 2018 December 31, 2017

Other receivables (Note 13) - 44,676

Other payables (Note 21) 523,013 282,755

Receivables from insurance operations 427,921 309,498

Payables to medical network 37,400,135 41,626,462

As at and for the year ended December 31, 2018 and 2017, transactions with related parties are as follows:

December 31, 2018 December 31, 2017

Premiums written 17,377,261 15,707,747

Claims incurred 333,700,186 275,503,160

Operating expense 1,940,906 16,955,389

Operating income 446,687 609,810

As for the year ended December 31, 2018, salaries and similar benefits provided to the senior management

including Chairman, Member of the Board of Directors, General Manager and Assistant General

Managers amounted to TL 13,867,221 (December 31, 2017: TL 6,779,863).

32 Contingencies

As at December 31, 2018 and 2017, total insurance risk accepted by the Group under normal courses of the

insurance business is detailed in Note 5 – Management of Insurance Risk.

As at December 31, 2018 and 2017, future minimum rentals payable under non-cancellable operating

leases for the rent of head office, regional offices and car rentals are as follows:

December 31, 2018 December 31, 2017

Within one year 2,102,859 1,480,587

After one year but not more than five years 2,300,572 2,128,274

Total 4,403,431 3,608,861

Acıbadem Sağlık ve Hayat Sigorta Anonim Şirketi and Its Subsidiary Notes to the Consolidated Financial Statements As at and For the Year Ended December 31, 2018 (Currency: Turkish Lira (TL) unless otherwise indicated)

54

33 Subsidiaries

The table below sets out the subsidiaries and shows their shareholding structure as at December 31, 2018 and, 2017:

Subsidiaries Direct shareholding

interest (%) Indirect shareholding

interest (%) Acıbadem Grubu Sigorta Aracılık Hizmetleri AŞ 100.00 100.00

Acıbadem Grubu Sigorta Aracılık Hizmetleri Anonim Şirketi (“ASA”) was established in 2010 to operate as an insurance agency in Turkey and foreign countries, to act as an intermediary in insurance and pension business contracts. Beside these operations, ASA can operate in other areas with the proposal of the Board and approval of the General Assembly, which are necessary and beneficial for the entity. ASA is consolidated under the Company in the accompanying consolidated financial statements.

34 Other

As a result of the reassessment performed by JCR Eurasia Rating in 2018, the credit rating of AA (Trk) on the long term national scale along with a positive outlook has been confirmed. Long term international foreign and local currency ratings have been confirmed as BBB, above the country ceiling. Other notes and details of the ratings are as follows:

Long Term International Foreign Currency : BBB / (Positive Outlook)

Long Term International Local Currency : BBB / (Positive Outlook)

Long Term National Local Rating : AA (Trk) / (Positive Outlook)

Short Term International Foreign Currency : A-3 / (Positive Outlook)

Short Term International Local Currency : A-3 / (Positive Outlook)

Short Term National Local Rating : A-1+ (Trk) / (Positive Outlook)

Sponsor Support : 2

Stand Alone : AB

35 Subsequent Event

Bupa International Limited, a part of BUPA Group has acquired the 100% of the Group’s shares, representing 100% of paid in capital from Burau Ventures Sdn Bhd and share transfer was completed on January 17, 2019.